Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 45
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis

  • Agraz-Doblas, Antonio
  • Bueno, Clara
  • Bashford-Rogers, Rachael
  • Roy, Anindita
  • Schneider, Pauline
  • Bardini, Michela
  • Ballerini, Paola
  • Cazzaniga, Gianni
  • Moreno, Thaidy
  • Revilla, Carlos
  • Gut, Marta
  • Valsecchi, Maria G.
  • Roberts, Irene
  • Pieters, Rob
  • De Lorenzo, Paola
  • Varela, Ignacio
  • Menéndez, Pablo
  • Stam, Ronald W.
B-cell acute lymphoblastic leukemia is the commonest childhood cancer. In infants, B-cell acute lymphoblastic leukemia remains fatal, especially in patients with t(4;11), present in ~80% of cases. The pathogenesis of t(4;11)/KMT2A-AFF1+ (MLL-AF4+) infant B-cell acute lymphoblastic leukemia remains difficult to model, and the pathogenic contribution in cancer of the reciprocal fusions resulting from derivative translocated-chromosomes remains obscure. Here, "multi-layered" genome-wide analyses and validation were performed on a total of 124 de novo cases of infant B-cell acute lymphoblastic leukemia uniformly diagnosed and treated according to the Interfant 99/06 protocol. These patients showed the most silent mutational landscape reported so far for any sequenced pediatric cancer. Recurrent mutations were exclusively found in K-RAS and N-RAS, were subclonal and were frequently lost at relapse, despite a larger number of non-recurrent/non-silent mutations. Unlike non-MLL-rearranged B-cell acute lymphoblastic leukemias, B-cell receptor repertoire analysis revealed minor, non-expanded B-cell clones in t(4;11)+ infant B-cell acute lymphoblastic leukemia, and RNA-sequencing showed transcriptomic similarities between t(4;11)+ infant B-cell acute lymphoblastic leukemias and the most immature human fetal liver hematopoietic stem and progenitor cells, confirming a "pre-VDJ" fetal cellular origin for both t(4;11) and RAS mut The reciprocal fusion AF4-MLL was expressed in only 45% (19/43) of the t(4;11)+ patients, and HOXA cluster genes are exclusively expressed in AF4-MLL-expressing patients. Importantly, AF4-MLL/HOXA-expressing patients had a significantly better 4-year event-free survival (62.4% vs 11.7%, P=0.001), and overall survival (73.7 vs 25.2%, P=0.016). AF4-MLL expression retained its prognostic significance when analyzed in a Cox model adjusting for risk stratification according to the Interfant-06 protocol based on age at diagnosis, white blood cell count and response to prednisone. This study has clinical implications for disease outcome and diagnostic risk-stratification of t(4;11)+ infant B-cell acute lymphoblastic leukemia., The human fetal material was provided by the Joint MRC/Wellcome Trust (grant# MR/R006237/1) Human Developmental Biology Resource (http://hdbr.org). This work was supported by the European Research Council (CoG-2014-646903 to PM; and StG-2014-637904 to IV), the Spanish Ministry of Economy and Competitiveness (SAF-SAF2013-43065 to PM and SAF2016-76758-R to IV), the Asociación Española Contra el Cáncer (AECC-CI-2015), FERO Foundation, and the ISCIII (PI14-01191) to CB. PM/IV also acknowledge financial support from The Obra Social La Caixa-Fundaciò Josep Carreras, The Inocente Inocente Foundation, Fundación Ramón Areces and The Generalitat de Catalunya (SGR330). IR was supported by a Programme Grant from Bloodwise (LLR 13001). PM is an investigator of the Spanish Cell Therapy cooperative network (TERCEL). AR was supported by a Clinician Scientist Fellowship from Bloodwise (14041)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Robustness of catalytically dead Cas9 activators in human pluripotent and mesenchymal stem cells

  • Petazzi, Paolo
  • Torres-Ruiz, Raul
  • Fidanza, Antonella
  • Roca-Ho, Heleia
  • Gutierrez-Agüera, Francisco
  • Castaño, Julio
  • Rodríguez-Perales, Sandra
  • Diaz de la Guardia, Rafael
  • López-Millán, Belén
  • Bigas Salvans, Anna
  • Forrester, Lesley M.
  • Bueno, Clara
  • Menéndez, Pablo
Human pluripotent stem cells (hPSCs) and mesenchymal stromal/stem cells (hMSCs) are clinically relevant sources for cellular therapies and for modeling human development and disease. Many stem cell-based applications rely on the ability to activate several endogenous genes simultaneously to modify cell fate. However, genetic intervention of these cells remains challenging. Several catalytically dead Cas9 (dCas9) proteins fused to distinct activation domains can modulate gene expression when directed to their regulatory regions by a specific single-guide RNA (sgRNA). In this study, we have compared the ability of the first-generation dCas9-VP64 activator and the second-generation systems, dCas9-SAM and dCas9-SunTag, to induce gene expression in hPSCs and hMSCs. Several stem cell lines were tested for single and multiplexed gene activation. When the activation of several genes was compared, all three systems induced specific and potent gene expression in both single and multiplexed settings, but the dCas9-SAM and dCas9-SunTag systems resulted in the highest and most consistent level of gene expression. Simultaneous targeting of the same gene with multiple sgRNAs did not result in additive levels of gene expression in hPSCs nor hMSCs. We demonstrate the robustness and specificity of second-generation dCas9 activators as tools to simultaneously activate several endogenous genes in clinically relevant human stem cells., We thank CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for their institutional support. We thank Jose Luis Sardina (IJC, Barcelona) for technical assistance with the teratoma assays. Financial support for this work was obtained from the Catalunya Goverment (SGR330 and PERIS 2017-2019), the Spanish Ministry of Economy and Competitiveness (SAF2016-80481-R), the European Research Council (CoG-2014-646903), and the Fundación Leo Messi to P.M.; the Spanish Association against Cancer (AECC-CI-2015) and the Health Institute Carlos III (ISCIII/FEDER, PI17/01028) to C.B.; the Biotechnology and Biological Sciences Research Council (BBRSC) to L.M.F. and A.F.; and the Spanish National Research and Development Plan (ISCIII/FEDER, PI17/02303) and the AEI/MICIU EXPLORA Project (BIO2017-91272-EXP) to S.R.-P. P.M. is an investigator of the Spanish Cell Therapy Cooperative Network (TERCEL). R.T.-R. is supported by a postdoctoral fellowship from the Asociación Española Contra el Cáncer (AECC).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL

  • Prieto, Cristina
  • Iglesias Coma, Mar
  • Menéndez, Pablo
Mixed-lineage leukemia (MLL)-rearranged (MLLr) infant B-cell acute lymphoblastic leukemia (iMLLr-B-ALL) has a dismal prognosis and is associated with a pro-B/mixed phenotype, therapy refractoriness and frequent central nervous system (CNS) disease/relapse. Neuron-glial antigen 2 (NG2) is specifically expressed in MLLr leukemias and is used in leukemia immunophenotyping because of its predictive value for MLLr acute leukemias. NG2 is involved in melanoma metastasis and brain development; however, its role in MLL-mediated leukemogenesis remains elusive. Here we evaluated whether NG2 distinguishes leukemia-initiating/propagating cells (L-ICs) and/or CNS-infiltrating cells (CNS-ICs) in iMLLr-B-ALL. Clinical data from the Interfant cohort of iMLLr-B-ALL demonstrated that high NG2 expression associates with lower event-free survival, higher number of circulating blasts and more frequent CNS disease/relapse. Serial xenotransplantation of primary MLL-AF4+ leukemias indicated that NG2 is a malleable marker that does not enrich for L-IC or CNS-IC in iMLLr-B-All. However, NG2 expression was highly upregulated in blasts infiltrating extramedullar hematopoietic sites and CNS, and specific blockage of NG2 resulted in almost complete loss of engraftment. Indeed, gene expression profiling of primary blasts and primografts revealed a migratory signature of NG2+ blasts. This study provides new insights on the biology of NG2 in iMLLr-B-ALL and suggests NG2 as a potential therapeutic target to reduce the risk of CNS disease/relapse and to provide safer CNS-directed therapies for iMLLr-B-ALL., This work was supported by the European Research Council (CoG-2014-646903) and the Spanish Ministry of Economy-Competitiveness (SAF-SAF2013-43065) to PM, the Asociación Española Contra el Cáncer to CB and the ISCIII/FEDER (PI14/01191-PI13/00168) to CB and JCRM. PM acknowledges the financial support from the Obra Social La Caixa-Fundaciò Josep Carreras, the Inocente-Inocente Foundation and Generalitat de Catalunya. CP and DRM were funded by PFIS scholarships from the ISCIII. VA has financial support from L’Oreal-UNESCO. PM is investigator of the Spanish Cell Therapy cooperative network (TERCEL). We thank Antonio Agraz/Ignacio Varela (IBBTEC, Santander) for assisting in microarray analysis. We also thank Dr Patricia Pérez-Galán and Gael Roue (IDIBAPS, Barcelona, Spain) for helpful discussions on NG2 blocking experiments.
Repisalud
Publication Artículo científico (JournalArticle)

Genetic Rescue of Mitochondrial and Skeletal Muscle Impairment in an Induced Pluripotent Stem Cells Model of Coenzyme Q10 Deficiency.

  • Romero-Moya, Damià
  • Santos-Ocaña, Carlos
  • Castaño, Julio
  • Garrabou, Gloria
  • Rodríguez-Gómez, José A
  • Ruiz-Bonilla, Vanesa
  • Bueno, Clara
  • González-Rodríguez, Patricia
  • Giorgetti, Alessandra
  • Perdiguero, Eusebio
  • Prieto, Cristina
  • Moren-Nuñez, Constanza
  • Fernández-Ayala, Daniel J
  • Cascajo, Maria Victoria
  • Velasco, Iván
  • Canals, Josep Maria
  • Montero, Raquel
  • Yubero, Delia
  • Jou, Cristina
  • López-Barneo, José
  • Cardellach, Francesc
  • Munoz-Canoves, Pura
  • Artuch, Rafael
  • Navas, Placido
  • Menéndez, Pablo
Coenzyme Q10 (CoQ10 ) plays a crucial role in mitochondria as an electron carrier within the mitochondrial respiratory chain (MRC) and is an essential antioxidant. Mutations in genes responsible for CoQ10 biosynthesis (COQ genes) cause primary CoQ10 deficiency, a rare and heterogeneous mitochondrial disorder with no clear genotype-phenotype association, mainly affecting tissues with high-energy demand including brain and skeletal muscle (SkM). Here, we report a four-year-old girl diagnosed with minor mental retardation and lethal rhabdomyolysis harboring a heterozygous mutation (c.483G > C (E161D)) in COQ4. The patient's fibroblasts showed a decrease in [CoQ10 ], CoQ10 biosynthesis, MRC activity affecting complexes I/II + III, and respiration defects. Bona fide induced pluripotent stem cell (iPSCs) lines carrying the COQ4 mutation (CQ4-iPSCs) were generated, characterized and genetically edited using the CRISPR-Cas9 system (CQ4ed -iPSCs). Extensive differentiation and metabolic assays of control-iPSCs, CQ4-iPSCs and CQ4ed -iPSCs demonstrated a genotype association, reproducing the disease phenotype. The COQ4 mutation in iPSC was associated with CoQ10 deficiency, metabolic dysfunction, and respiration defects. iPSC differentiation into SkM was compromised, and the resulting SkM also displayed respiration defects. Remarkably, iPSC differentiation in dopaminergic or motor neurons was unaffected. This study offers an unprecedented iPSC model recapitulating CoQ10 deficiency-associated functional and metabolic phenotypes caused by COQ4 mutation. Stem Cells 2017;35:1687-1703.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment

  • Urdinguio, Rocío G.
  • Lopez, Virginia
  • Bayón, Gustavo F.
  • Diaz de la guardia, Rafael
  • Sierra, Marta I.
  • García Toraño, Estela
  • Perez, Raúl F.
  • García, María G.
  • Carella, Antonella
  • Pruneda, Patricia C.
  • Prieto, Cristina
  • Dmitrijeva, Marija
  • Santamarina, Pablo
  • Belmonte, Thalía
  • Mangas, Cristina
  • Diaconu, Elena
  • Ferrero, Cecilia
  • Tejedor, Juan Ramón
  • Fernandez Morera, Juan Luis
  • Bravo, Cristina
  • Bueno, Clara
  • Sanjuan Pla, Alejandra
  • Rodriguez, Ramon M.
  • Suarez Alvarez, Beatriz
  • López Larrea, Carlos
  • Bernal, Teresa
  • Colado, Enrique
  • Balbín, Milagros
  • García Suarez, Olivia
  • Chiara, María Dolores
  • Sáenz de Santa María, Inés
  • Rodríguez, Francisco
  • Pando Sandoval, Ana
  • Rodrigo, Luis
  • Santos, Laura
  • Salas, Anna
  • Vallejo Díaz, Jesús
  • Carrera, Ana C.
  • Rico, Daniel
  • Hernández López, Inmaculada
  • Vayá, Amparo
  • Ricart, Josep M.
  • Seto, Edward
  • Sima Teruel, Núria
  • Vaquero García, Alejandro
  • Valledor, Luis
  • Cañal, Maria Jesus
  • Pisano, David
  • Graña Castro, Osvaldo
  • Thomas, Tim
  • Voss, Anne K.
  • Menéndez, Pablo
  • Villar Garea, Ana
  • Deutzmann, Rainer
  • Fernandez, Agustín F.
  • Fraga, Mario F.
Histone H4 acetylation at Lysine 16 (H4K16ac) is a key epigenetic mark involved in gene regulation, DNA repair and chromatin remodeling, and though it is known to be essential for embryonic development, its role during adult life is still poorly understood. Here we show that this lysine is massively hyperacetylated in peripheral neutrophils. Genome-wide mapping of H4K16ac in terminally differentiated blood cells, along with functional experiments, supported a role for this histone post-translational modification in the regulation of cell differentiation and apoptosis in the hematopoietic system. Furthermore, in neutrophils, H4K16ac was enriched at specific DNA repeats. These DNA regions presented an accessible chromatin conformation and were associated with the cleavage sites that generate the 50 kb DNA fragments during the first stages of programmed cell death. Our results thus suggest that H4K16ac plays a dual role in myeloid cells as it not only regulates differentiation and apoptosis, but it also exhibits a non-canonical structural role in poising chromatin for cleavage at an early stage of neutrophil cell death.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens

  • Vidal Crespo, Anna
  • Matas Céspedes, Alba
  • Rodríguez, Vanina
  • Rossi, Cédric
  • Valero, Juan G.
  • Serrat Aymerich, Neus
  • Sanjuan Pla, Alejandra
  • Menéndez Buján, Pablo
  • Roué, Gaël
  • López Guillermo, Armando
  • Giné Soca, Eva
  • Campo Güerri, Elias
  • Colomer Pujol, Dolors
  • Bezombes, Christine
  • Lammerts van Bueren, J.
  • Chiu, Christopher
  • Doshi, Parul
  • Pérez Galán, Patricia
CD38 is expressed in several types of non-Hodgkin lymphoma and constitutes a promising target for antibody-based therapy. Daratumumab (Darzalex) is a first-in-class anti-CD38 antibody approved for the treatment of relapsed/refractory multiple myeloma. It has also demonstrated clinical activity in Waldenstrom macroglobulinaemia and amyloidosis. Here, we have evaluated the activity and mechanism of action of daratumumab in preclinical in vitro and in vivo models of mantle cell lymphoma, follicular lymphoma and diffuse large B cell lymphoma, as monotherapy or in combination with standard chemo-immunotherapy. In vitro, daratumumab engages Fc-mediated cytotoxicity by antibody-dependent cell cytotoxicity and antibody-dependent cell phagocytosis in all lymphoma subtypes. In the presence of human serum, complement-dependent cell cytotoxicity was marginally engaged. We demonstrated by Selective Plane Illumination Microscopy that daratumumab fully penetrated a 3D lymphoma organoid and decreased organoid volume. In vivo, daratumumab completely prevents tumor outgrowth in models of mantle cell and follicular lymphoma, and shows comparable activity to rituximab in a disseminated in vivo model of blastic mantle cell lymphoma. Moreover, daratumumab improves overall survival in a mouse model of transformed CD20dim follicular lymphoma, where rituximab showed limited activity. Daratumumab potentiates the antitumor activity of CHOP and R-CHOP in mantle cell and follicular lymphoma xenografts. Furthermore, in a patient-derived diffuse large B cell lymphoma xenograft model, daratumumab anti-tumor activity was comparable to R-CHOP and the addition of daratumumab to either CHOP or R-CHOP led to full tumor regression. In summary, daratumumab constitutes a novel therapeutic opportunity in certain scenarios and these results warrant further clinical development.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Developmental refractoriness of MLL-rearranged human B-cell acute leukemias to reprogramming into pluripotency

  • Muñoz, Alvaro
  • Romero Moya, Damià
  • Prieto, Cristina
  • Ramos-Mejía, Verónica
  • Agraz-Doblas, Antonio
  • Varela, Ignacio
  • Buschbeck, Marcus
  • Palau de Miguel, Anna
  • Carvajal-Vergara, Xonia
  • Giorgetti, Alessandra
  • Ford, Anthony
  • Lako, Majlinda
  • Granada, Isabel
  • Ruiz-Xivillé, Neus
  • Rodríguez-Perales, Sandra
  • Torres-Ruíz, Raul
  • Stam, Ronald W.
  • Fuster, Jose Luis
  • Fraga, Mario F.
  • Nakanishi, Mahito
  • Cazzaniga, Gianni
  • Bardini, Michela
  • Cobo, Isabel
  • Bayón, Gustavo F.
  • Fernández, Agustín F.
  • Bueno, Clara
  • Menéndez Buján, Pablo
Induced pluripotent stem cells (iPSCs) are a powerful tool for disease modeling. They are routinely generated from healthy donors and patients from multiple cell types at different developmental stages. However, reprogramming leukemias is an extremely inefficient process. Few studies generated iPSCs from primary chronic myeloid leukemias, but iPSC generation from acute myeloid or lymphoid leukemias (ALL) has not been achieved. We attempted to generate iPSCs from different subtypes of B-ALL to address the developmental impact of leukemic fusion genes. OKSM(L)-expressing mono/polycistronic-, retroviral/lentiviral/episomal-, and Sendai virus vector-based reprogramming strategies failed to render iPSCs in vitro and in vivo. Addition of transcriptomic-epigenetic reprogramming 'boosters' also failed to generate iPSCs from B cell blasts and B-ALL lines, and when iPSCs emerged they lacked leukemic fusion genes, demonstrating non-leukemic myeloid origin. Conversely, MLL-AF4-overexpressing hematopoietic stem cells/B progenitors were successfully reprogrammed, indicating that B cell origin and leukemic fusion gene were not reprogramming barriers. Global transcriptome/DNA methylome profiling suggested a developmental/differentiation refractoriness of MLL-rearranged B-ALL to reprogramming into pluripotency.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Development of a novel anti-CD19 chimeric antigen receptor: A paradigm for an affordable CAR T cell production at academic institutions

  • Castellà Castellà, Maria
  • Boronat, Anna
  • Martín Ibáñez, Raquel
  • Rodríguez, Vanina
  • Suñé, Guillermo
  • Caballero, Miguel
  • Marzal Martí, Berta
  • Pérez-Amill, Lorena
  • Martín-Antonio, Beatriz
  • Castaño, Julio
  • Bueno, Clara
  • Balagué, Olga
  • González Navarro, E. Azucena
  • Serra Pagès, Carles
  • Engel Rocamora, Pablo
  • Vilella, Ramon
  • Benítez-Ribas, Daniel
  • Ortiz-Maldonado Gibson, Valentín
  • Cid Vidal, Joan
  • Tabera, Jaime
  • Canals i Coll, Josep M.
  • Lozano, Miquel
  • Baumann, Tycho
  • Vilarrodona, Anna
  • Trias, Esteve
  • Campo Güerri, Elias
  • Menéndez Buján, Pablo
  • Urbano Ispizua, Álvaro
  • Yagüe, Jordi
  • Pérez Galán, Patricia
  • Rives Solà, Susana
  • Delgado, Julio (Delgado González)
  • Juan, Manel
Genetically modifying autologous T cells to express an anti-CD19 chimeric antigen receptor (CAR) has shown impressive response rates for the treatment of CD19+ B cell malignancies in several clinical trials (CTs). Making this treatment available to our patients prompted us to develop a novel CART19 based on our own anti-CD19 antibody (A3B1), followed by CD8 hinge and transmembrane region, 4-1BB- and CD3z-signaling domains. We show that A3B1 CAR T cells are highly cytotoxic and specific against CD19+ cells in vitro, inducing secretion of pro-inflammatory cytokines and CAR T cell proliferation. In vivo, A3B1 CAR T cells are able to fully control disease progression in an NOD.Cg-Prkdcscid Il2rdtm1Wjl/SzJ (NSG) xenograph B-ALL mouse model. Based on the pre-clinical data, we conclude that our CART19 is clearly functional against CD19+ cells, to a level similar to other CAR19s currently being used in the clinic. Concurrently, we describe the implementation of our CAR T cell production system, using lentiviral vector and CliniMACS Prodigy, within a medium-sized academic institution. The results of the validation phase show our system is robust and reproducible, while maintaining a low cost that is affordable for academic institutions. Our model can serve as a paradigm for similar institutions, and it may help to make CAR T cell treatment available to all patients.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Proinflammatory signals are insufficient to drive definitive hematopoietic specification of human HSCs in vitro

  • Giorgetti, Alessandra
  • Castaño, Julio
  • Bueno, Clara
  • Diaz de la Guardia, Rafael
  • Delgado, Mario
  • Bigas Salvans, Anna
  • Espinosa, Lluís
  • Menéndez Buján, Pablo
Recent studies in zebrafish and mice have revealed that proinflammatory signaling is a positive regulator of definitive hematopoietic development. Whether proinflammatory signaling also regulates human hematopoietic specification remains unknown. Here, we explored the impact of the proinflammatory cytokines tumor necrosis factor-α (TNFα), interferon-γ (IFNγ), and interleukin-1β (IL1β) on in vitro hematopoietic differentiation using human pluripotent stem cells. Gene expression analysis and enzyme-linked immunosorbent assay revealed the absence of a proinflammatory signature during hematopoietic development of human pluripotent stem cells. Functionally, the emergence of hemogenic endothelial progenitors (CD31+CD34+CD45− or CD34+CD43−CD73−) and hematopoietic cells (CD43+CD45+) was not affected by treatment with increasing doses of TNFα, IFNγ, and IL1β irrespective of the developmental window or the differentiation protocol used (embryoid body or OP9 co-culture based). Similarly, knockdown of endogenous NF-kB signaling had no impact on hematopoietic differentiation of human pluripotent stem cells. This study serves as a demonstration that TNFα, IFNγ, and IL1β signals do not improve hematopoietic differentiation of human pluripotent stem cells using current protocols and suggests that proinflammatory signaling is insufficient to drive definitive hematopoietic specification of human hematopoietic stem cells in vitro.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

GATA2 Promotes Hematopoietic Development and Represses Cardiac Differentiation of Human Mesoderm

  • Castaño, Julio
  • Aranda, Sergi
  • Bueno, Clara
  • Calero-Nieto, Fernando J.
  • Mejia-Ramirez, Eva
  • Mosquera Mayo, José Luís
  • Blanco, Enrique
  • Wang, Xiaonan
  • Prieto Rios, Cristina
  • Zabaleta, Lorea
  • Mereu, Elisabetta
  • Rovira, Meritxell
  • Jiménez-Delgado, Senda
  • Matson, Daniel R.
  • Heyn, Holger
  • Bresnick, Emery H.
  • Göttgens, Berthold
  • Di Croce, Luciano
  • Menéndez Buján, Pablo
  • Raya Chamorro, Ángel
  • Giorgetti, Alessandra
In vertebrates, GATA2 is a master regulator of hematopoiesis and is expressed throughout embryo development and in adult life. Although the essential role of GATA2 in mouse hematopoiesis is well established, its involvement during early human hematopoietic development is not clear. By combining time-controlled overexpression of GATA2 with genetic knockout experiments, we found that GATA2, at the mesoderm specification stage, promotes the generation of hemogenic endothelial progenitors and their further differentiation to hematopoietic progenitor cells, and negatively regulates cardiac differentiation. Surprisingly, genome-wide transcriptional and chromatin immunoprecipitation analysis showed that GATA2 bound to regulatory regions, and repressed the expression of cardiac development-related genes. Moreover, genes important for hematopoietic differentiation were upregulated by GATA2 in a mostly indirect manner. Collectively, our data reveal a hitherto unrecognized role of GATA2 as a repressor of cardiac fates, and highlight the importance of coordinating the specification and repression of alternative cell fates.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Genetic rescue of mitochondrial and skeletal muscle impairment in an induced pluripotent stem cells model of coenzyme Q10 deficiency

  • Romero-Moya, Damià
  • Santos-Ocaña, Carlos
  • Castaño, Justo P.
  • Rodríguez-Gómez, José A.
  • González-Rodríguez, Patricia
  • Fernández-Ayala, Daniel J. M.
  • Cascajo Almenara, M. V.
  • Montero, Raquel
  • Yubero, Delia
  • López-Barneo, José
  • Muñoz-Cánoves, Pura
  • Artuch, Rafael
  • Navas, Plácido
  • Menéndez, Pablo
et al., Coenzyme Q (CoQ) plays a crucial role in mitochondria as an electron carrier within the mitochondrial respiratory chain (MRC) and is an essential antioxidant. Mutations in genes responsible for CoQ biosynthesis (COQ genes) cause primary CoQ deficiency, a rare and heterogeneous mitochondrial disorder with no clear genotype–phenotype association, mainly affecting tissues with high-energy demand including brain and skeletal muscle (SkM). Here, we report a four-year-old girl diagnosed with minor mental retardation and lethal rhabdomyolysis harboring a heterozygous mutation (c.483G > C (E161D)) in COQ4. The patient's fibroblasts showed a decrease in [CoQ], CoQ biosynthesis, MRC activity affecting complexes I/II + III, and respiration defects. Bona fide induced pluripotent stem cell (iPSCs) lines carrying the COQ4 mutation (CQ4-iPSCs) were generated, characterized and genetically edited using the CRISPR-Cas9 system (CQ4-iPSCs). Extensive differentiation and metabolic assays of control-iPSCs, CQ4-iPSCs and CQ4-iPSCs demonstrated a genotype association, reproducing the disease phenotype. The COQ4 mutation in iPSC was associated with CoQ deficiency, metabolic dysfunction, and respiration defects. iPSC differentiation into SkM was compromised, and the resulting SkM also displayed respiration defects. Remarkably, iPSC differentiation in dopaminergic or motor neurons was unaffected. This study offers an unprecedented iPSC model recapitulating CoQ deficiency-associated functional and metabolic phenotypes caused by COQ4 mutation., This work was supported by the ISCIII/FEDER (E-Rare-2 Call PI12/03112 to P.M.), FIS/ISCIII/FEDER project (PI14/01962 to P.N.) and the European Research Council (ERC-2014-CoG646903 to P.M.). D.R.M. and C.P. are supported by PFIS scholarships (FI11/0511 and FI12/00468, respectively). C.B is supported by a Miguel Servet II contract (CPII13/00011). P.M. also acknowledges the financial support from The Obra Social La Caixa-Fundacio Josep Carreras and The Generalitat de Catalunya (SGR330). P.M. and J.L.-B. are investigators of the Spanish Cell Therapy cooperative network (TERCEL). A.G. is supported by Ramon y Cajal Program (RyC-2013–13221)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Development refractoriness of MLL-rearranged human B cell acute leukemias to reprogramming into pluripotency

  • Muñoz-López, Alvaro
  • Prieto López, Cristina
  • Agraz-Doblas, Antonio
  • Varela, Ignacio
  • Menéndez, Pablo
et al., Induced pluripotent stem cells (iPSCs) are a powerful tool for disease modeling. They are routinely generated from healthy donors and patients from multiple cell types at different developmental stages. However, reprogramming leukemias is an extremely inefficient process. Few studies generated iPSCs from primary chronic myeloid leukemias, but iPSC generation from acute myeloid or lymphoid leukemias (ALL) has not been achieved. We attempted to generate iPSCs from different subtypes of B-ALL to address the developmental impact of leukemic fusion genes. OKSM(L)-expressing mono/polycistronic-, retroviral/lentiviral/episomal-, and Sendai virus vector-based reprogramming strategies failed to render iPSCs in vitro and in vivo. Addition of transcriptomic-epigenetic reprogramming “boosters” also failed to generate iPSCs from B cell blasts and B-ALL lines, and when iPSCs emerged they lacked leukemic fusion genes, demonstrating non-leukemic myeloid origin. Conversely, MLL-AF4-overexpressing hematopoietic stem cells/B progenitors were successfully reprogrammed, indicating that B cell origin and leukemic fusion gene were not reprogramming barriers. Global transcriptome/DNA methylome profiling suggested a developmental/differentiation refractoriness of MLL-rearranged B-ALL to reprogramming into pluripotency., This work was supported by the European Research Council to P.M. (ERC-2014-CoG-646903), the ISCIII/FEDER (E-Rare-2 Call PI12/03112 to P.M. and PI14/01191 to C.B.), MINECO (SAF2013-43065 to P.M.), and the Spanish Association Against Cancer (AECC) to P.M. and C.B. C.B. is supported by a Miguel Servet II contract (CPII13/00011). D.R.M. and A.M.-L. are supported by PFIS (FI11/0511) and FPI (BES-2014-067844) scholarships, respectively. P.M. also acknowledges financial support from the Obra Social La Caixa, Fundaciò Josep Carreras and The Generalitat de Catalunya (SGR330). Open Access funded by European Research Council., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Intratumoral heterogeneity and clonal evolution in blood malignancies and solid tumors

  • Varela, Ignacio
  • Menéndez, Pablo
  • Sanjuan-Pla, Alejandra
This meeting held at the University of Barcelona in March 2017, brought together scientists and clinicians worldwide to discuss current and future clinico-biological implications of intratumoral heterogeneity (ITH) and subclonal evolution in cancer diagnosis, patient stratification, and treatment resistance in diagnosis, treatment and follow-up. There was consensus that both longitudinal and tumor multi-region studies in matched samples are needed to better understand the dynamics of ITH. The contribution of the epigenome and microenvironment to ITH and subclone evolution remains understudied. It was recommended to combine computational, pathology and imaging tools to study the role of the microenvironment in subclone selection/ evolution., I.V. is funded by Spanish Ministry of Economy and Competitiveness (SAF2016-76758-R), The Fundación Ramón Areces and European Research Council (ERC StG-2014-637904). P.M. is supported by European Research Council (CoG-2014-646903), Spanish Ministry of Economy and Competitiveness (SAF-2016-80481-R & RTC-2016-4603-1), Generalitat de Catalunya (SGR-330) and Obra Social La Caixa-Fundación Josep Carreras. A.S.P. is funded by Ramón & Cajal Program from Spanish Ministry of Economy and Competitiveness (RYC-2015- 17534) and Marie Curie Program from EU (FP7-PEOPLE- 2013-CIG 631171)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Expression of MLL-AF4 or AF4-MLL fusions does not impact the efficiency of DNA damage repair

  • Castaño, Julio
  • Herrero, Ana B.
  • Bursen, Aldeheid
  • González, Federico
  • Marschalek, Rolf
  • Gutiérrez, Norma Carmen
  • Menéndez, Pablo
The most frequent rearrangement of the human MLL gene fuses MLL to AF4 resulting in high-risk infant B-cell acute lymphoblastic leukemia (B-ALL). MLL fusions are also hallmark oncogenic events in secondary acute myeloid leukemia. They are a direct consequence of mis-repaired DNA double strand breaks (DNA-DSBs) due to defects in the DNA damage response associated with exposure to topoisomerase- II poisons such as etoposide. It has been suggested that MLL fusions render cells susceptible to additional chromosomal damage upon exposure to etoposide. Conversely, the genome-wide mutational landscape in MLL-rearranged infant B-ALL has been reported silent. Thus, whether MLL fusions compromise the recognition and/or repair of DNA damage remains unanswered. Here, the fusion proteins MLL-AF4 (MA4) and AF4-MLL (A4M) were CRISPR/Cas9-genome edited in the AAVS1 locus of HEK293 cells as a model to study MLL fusion-mediated DNA-DSB formation/repair. Repair kinetics of etoposide- and ionizing radiation-induced DSBs was identical in WT, MA4- and A4M-expressing cells, as revealed by flow cytometry, by immunoblot for γH2AX and by comet assay. Accordingly, no differences were observed between WT, MA4- and A4M-expressing cells in the presence of master proteins involved in non-homologous end-joining (NHEJ; i.e.KU86, KU70), alternative-NHEJ (Alt-NHEJ; i.e.LigIIIa, WRN and PARP1), and homologous recombination (HR, i.e.RAD51). Moreover, functional assays revealed identical NHEJ and HR efficiency irrespective of the genotype. Treatment with etoposide consistently induced cell cycle arrest in S/G2/M independent of MA4/A4M expression, revealing a proper activation of the DNA damage checkpoints. Collectively, expression of MA4 or A4M does neither influence DNA signaling nor DNA-DSB repair., This work was supported by the European Research Council to P.M (ERC-2014-CoG-646903), MINECO (SAF2013-43065 to P.M), The Foundation Inocente Inocente and the Spanish Association of Cancer Research (AECC) to P.M and the Deutsche José Carreras Leukämie Stiftung to R.M/P.M. P.M also acknowledges the financial support from The Obra Social La Caixa-Fundaciò Josep Carreras and The Generalitat de Catalunya (SGR330). F.G. is supported by a Ramón y Cajal Grant (RYC-2014-16751) from the Ministry of Economy and Competitiveness (MINECO), Spain. N.C.G and A.B.H acknowledge financial support from The Cooperative Research Thematic Networks (RTICC) (RD12/0036/0058) and the INNOCAMPUS Program (CEI10-1-0010)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment

  • Urdinguio, Rocío G.
  • López, Virginia
  • Bayón, Gustavo F.
  • Díaz de la Guardia, Rafael
  • Sierra, Marta I.
  • García-Toraño, Estela
  • Pérez, Raúl F.
  • García, María G.
  • Carella, Antonella
  • Pruneda, Patricia C.
  • Prieto López, Cristina
  • Dmitrijeva, Marija
  • Santamarina-Ojeda, Pablo
  • Belmonte, Thalia
  • Mangas, Cristina
  • Diaconu, Elena
  • Ferrero, Cecilia
  • Tejedor, Juan Ramón
  • Fernández-Morera, Juan L.
  • Bravo, Cristina
  • Bueno, Clara
  • Sanjuan-Pla, Alejandra
  • Rodríguez López, Ramón María
  • Suárez-Álvarez, Beatriz
  • López-Larrea, Carlos
  • Bernal, Teresa
  • Colado, Enrique
  • Balbín, Milagros
  • García-Suarez, Olivia
  • Chiara, María-Dolores
  • Sáenz-de-Santa-María, Inés
  • Rodríguez Hernández, Francisco José
  • Pando-Sandoval, Ana
  • Rodrigo, Luis
  • Santos, Laura
  • Salas, Ana
  • Vallejo-Díaz, Jesús
  • Carrera, Ana C.
  • Rico, Daniel
  • Hernández-López, Inmaculada
  • Vayá, Amparo
  • Ricart, José M.
  • Seto, Edward
  • Sima-Teruel, Núria
  • Vaquero, Alejandro
  • Valledor, Luis
  • Cañal, María Jesús
  • Pisano, David G.
  • Graña-Castro, Osvaldo
  • Thomas, Tim
  • Voss, Anne K.
  • Menéndez, Pablo
  • Villar-Garea, Ana
  • Deutzmann, Rainer
  • Fernández, Agustín F.
  • Fraga, Mario F.
Histone H4 acetylation at Lysine 16 (H4K16ac) is a key epigenetic mark involved in gene regulation, DNA repair and chromatin remodeling, and though it is known to be essential for embryonic development, its role during adult life is still poorly understood. Here we show that this lysine is massively hyperacetylated in peripheral neutrophils. Genome-wide mapping of H4K16ac in terminally differentiated blood cells, along with functional experiments, supported a role for this histone post-translational modification in the regulation of cell differentiation and apoptosis in the hematopoietic system. Furthermore, in neutrophils, H4K16ac was enriched at specific DNA repeats. These DNA regions presented an accessible chromatin conformation and were associated with the cleavage sites that generate the 50 kb DNA fragments during the first stages of programmed cell death. Our results thus suggest that H4K16ac plays a dual role in myeloid cells as it not only regulates differentiation and apoptosis, but it also exhibits a non-canonical structural role in poising chromatin for cleavage at an early stage of neutrophil cell death., Plan Nacional de I+D+I co-funding FEDER [PI15/00892 and PI18/01527 to M.F.F. and A.F.F.; PI16/01318 and PI14/01244 to C.L.]; ISCIII-Subdireccion General de Evaluacion y Fomento de la Investigacion, and Plan Nacional de I+D+I 2008–2011/FEDER [CP11/00131 to A.F.F.]; IUOPA (to G.F.B. and M.I.S.); Fundacion Cientifica de la AECC (to R.G.U.); Ministry of Economy and Competitiveness Juan de la Cierva postdoctoral fellowships [FJCI-2015-26965 to J.R.T., IJCI-2015- 23316 to V.L.]; Fundacion Ramon Areces (to M.F.F); FICYT (to E.G.T., M.G.G., A.C.); Asturias Regional Government [GRUPIN14-052 to M.F.F.]; Gobierno del Principado de Asturias, PCTI-Plan de Ciencia, Tecnologia e Innovacion co-funding Fondos FEDER (grant number IDI/2018/146 to M.F.F. and IDI/2018/144 to C.L.); Deutsche Forschungsgemeinschaft (DFG) [SFB960 to A.V.G., R.D.]; European Research Council [CoG-2014-646903]; Spanish Ministry of Economy and Competitiveness [SAF-SAF2013-43065 to P.M.]; Asociacion Española Contra el Cancer [AECC-CI-2015]; FERO Foundation, and the ISCIII [PI14-01191 to C.B.]; P.M. acknowledges financial support from The Obra Social La Caixa Fundacio Josep Carreras and The Generalitat de Catalunya (SGR330). P.M. an investigator from the Spanish Cell Therapy cooperative network (TERCEL). The IUOPA is supported by the Obra Social Liberbank-Cajastur, Spain. Funding for open access charge: Plan Nacional de I+D+I co-funding FEDER [PI18/01527].
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope

  • Velasco-Hernández, Talia
  • Zanetti, Samanta Romina
  • Roca-Ho, Heleia
  • Gutiérrez-Agüera, Francisco
  • Petazzi, Paolo
  • Sánchez-Martínez
  • Sánchez-Martínez, Diego
  • Molina, Oscar
  • Baroni, Matteo L.
  • Fuster, José Luis
  • Ballerini, Paola
  • Bueno, Clara
  • Fernández-Fuentes, Narcis
  • Engel, Pablo
  • Menéndez, Pablo
Background There are few therapeutic options available for patients with B-cell acute lymphoblastic leukemia (B-ALL) relapsing as CD19 - either after chemotherapy or CD19-targeted immunotherapies. CD22-chimeric antigen receptor (CAR) T cells represent an attractive addition to CD19-CAR T cell therapy because they will target both CD22 + CD19 - B-ALL relapses and CD19 - preleukemic cells. However, the immune escape mechanisms from CD22-CAR T cells, and the potential contribution of the epitope binding of the anti-CD22 single-chain variable fragment (scFv) remain understudied. Methods Here, we have developed and comprehensively characterized a novel CD22-CAR (clone hCD22.7) targeting a membrane-distal CD22 epitope and tested its cytotoxic effects against B-ALL cells both in in vitro and in vivo assays. Results Conformational epitope mapping, cross-blocking, and molecular docking assays revealed that the hCD22.7 scFv is a high-affinity binding antibody which specifically binds to the ESTKDGKVP sequence, located in the Ig-like V-type domain, the most distal domain of CD22. We observed efficient killing of B-ALL cells in vitro, although the kinetics were dependent on the level of CD22 expression. Importantly, we show an efficient in vivo control of patients with B-ALL derived xenografts with diverse aggressiveness, coupled to long-term hCD22.7-CAR T cell persistence. Remaining leukemic cells at sacrifice maintained full expression of CD22, ruling out CAR pressure-mediated antigen loss. Finally, the immunogenicity capacity of this hCD22.7-scFv was very similar to that of other CD22 scFv previously used in adoptive T cell therapy. Conclusions We report a novel, high-affinity hCD22.7 scFv which targets a membrane-distal epitope of CD22. 4-1BB-based hCD22.7-CAR T cells efficiently eliminate clinically relevant B- CD22 high and CD22 low ALL primary samples in vitro and in vivo. Our study supports the clinical translation of this hCD22.7-CAR as either single or tandem CD22-CD19-CAR for both naive and anti-CD19-resistant patients with B-ALL., This work was supported by the European Research Council (CoG-2014- 646903, PoC-2018-811220), the Spanish Ministry of Economy and Competitiveness (MINECO-SAF2016-80481-R), the Fundación Uno entre Cienmil, the Obra Social La Caixa (LCF/PR/HR19/52160011), the Spanish Cancer Association and Leo Messi Foundation to PM. CB was supported by the ISCIII/FEDER (PI17/01028). TVH and SRZ were supported by Marie Sklodowska Curie Fellowships (792923 and 795833, respectively). DSM was supported by a Sara Borrell fellowship from the ISCIII. MLB was supported by a FPI scholarship from the MINECO. PM is an investigator of the Spanish Cell Therapy Network (TERCEL).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Research data Set de datos (Dataset)

Epigenome-wide analysis reveals specific DNA hypermethylation of T cells during human hematopoietic differentiation

  • Tejedor, Juan Ramón
  • Bueno, Clara
  • Cobo, Isabel
  • Bayón, Gustavo F.
  • Prieto López, Cristina
  • Mangas, Cristina
  • Pérez, Raúl F.
  • Santamarina-Ojeda, Pablo
  • Urdinguio, Rocío G.
  • Menéndez, Pablo
  • Fraga, Mario F.
  • Fernández, Agustín F.
Supplementary figures and supplementary data tables from MethylationEPIC arrays (Tejedor et al), plus a compiled dataset including raw methylation intensities, processed β-values and Phenotypic data from HumanMethylation450 arrays collected from datasets GSE63409, GSE49618, GSE88824 and GSE49031, and HumanMethylationEPIC arrays deposited in E-MTAB-6315 entry from ArrayExpress., Epigenetic regulation plays an important role in cellular development and differentiation. A detailed map of the DNA methylation dynamics that occur during cell differentiation would contribute to decipher the molecular networks governing cell fate commitment. In this study we used the most recent Illumina MethylationEPIC Beadchip platform to describe the genome-wide DNA methylation changes observed throughout hematopoietic maturation by analyzing multiple hematopoietic cell types at different developmental stages., Grants: European Commission: INFANTLEUKEMIA - GENOMIC, CELLULAR AND DEVELOPMENTAL RECONSTRUCTION OFINFANT MLL-AF4+ ACUTE LYMPHOBLASTIC LEUKEMIA (646903)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Research data Set de datos (Dataset)

Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment

  • Urdinguio, Rocío G.
  • López, Virginia
  • Bayón, Gustavo F.
  • Díaz de la Guardia, Rafael
  • Sierra, Marta I.
  • García-Toraño, Estela
  • Pérez, Raúl F.
  • García, María G.
  • Carella, Antonella
  • Pruneda, Patricia C.
  • Prieto López, Cristina
  • Dmitrijeva, Marija
  • Santamarina-Ojeda, Pablo
  • Belmonte, Thalia
  • Mangas, Cristina
  • Diaconu, Elena
  • Ferrero, Cecilia
  • Tejedor, Juan Ramón
  • Fernández-Morera, Juan L.
  • Bravo, Cristina
  • Bueno, Clara
  • Sanjuan-Pla, Alejandra
  • Rodríguez López, Ramón María
  • Suárez-Álvarez, Beatriz
  • López-Larrea, Carlos
  • Bernal, Teresa
  • Colado, Enrique
  • Balbín, Milagros
  • García-Suarez, Olivia
  • Chiara, María-Dolores
  • Sáenz-de-Santa-María, Inés
  • Rodríguez Hernández, Francisco José
  • Pando-Sandoval, Ana
  • Rodrigo, Luis
  • Santos, Laura
  • Salas, Ana
  • Vallejo-Díaz, Jesús
  • Carrera, Ana C.
  • Rico, Daniel
  • Hernández-López, Inmaculada
  • Vayá, Amparo
  • Ricart, José M.
  • Seto, Edward
  • Sima-Teruel, Núria
  • Vaquero, Alejandro
  • Valledor, Luis
  • Cañal, María Jesús
  • Pisano, David G.
  • Graña-Castro, Osvaldo
  • Thomas, Tim
  • Voss, Anne K.
  • Menéndez, Pablo
  • Villar-Garea, Ana
  • Deutzmann, Rainer
  • Fernández, Agustín F.
  • Fraga, Mario F.
Supplementary data files corresponding to manuscript: Urdinguio, Lopez et al., Histone H4 acetylation at Lysine 16 (H4K16ac) is a key epigenetic mark involved in gene regulation, DNA repair and chromatin remodeling, and though it is known to be essential for embryonic development, its role during adult life is still poorly understood. Here we show that this lysine is massively hyperacetylated in peripheral neutrophils. Genome-wide mapping of H4K16ac in terminally differentiated blood cells, along with functional experiments, supported a role for this histone post-translational modification in the regulation of cell differentiation and apoptosis in the hematopoietic system. Furthermore, in neutrophils, H4K16ac was enriched at specific DNA repeats. These DNA regions presented an accessible chromatin conformation and were associated with the cleavage sites that generate the 50 kb DNA fragments during the first stages of programmed cell death. Our results thus suggest that H4K16ac plays a dual role in myeloid cells as it not only regulates differentiation and apoptosis, but it also exhibits a non-canonical structural role in poising chromatin for cleavage at an early stage of neutrophil cell death., European Commission: INFANTLEUKEMIA - GENOMIC, CELLULAR AND DEVELOPMENTAL RECONSTRUCTION OFINFANT MLL-AF4+ ACUTE LYMPHOBLASTIC LEUKEMIA (646903), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Integrative methylome-transcriptome analysis unravels cancer cell vulnerabilities in infant MLL-rearranged B cell acute lymphoblastic leukemia

  • Tejedor, Juan Ramón
  • Bueno, Clara
  • Vinyoles, Meritxell
  • Petazzi, Paolo
  • Agraz-Doblas, Antonio
  • Cobo, Isabel
  • Torres-Ruiz, Raúl
  • Bayón, Gustavo F.
  • Pérez, Raúl F.
  • López-Tamargo, Sara
  • Gutiérrez-Agüera, Francisco
  • Santamarina-Ojeda, Pablo
  • Ramírez-Orellana, Manuel
  • Bardini, Michela
  • Cazzaniga, Giovanni
  • Ballerini, Paola
  • Schneider, Paulina
  • Stam, Ronald W.
  • Varela, Ignacio
  • Fraga, Mario F.
  • Fernández, Agustín F.
  • Menéndez, Pablo
B cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer. As predicted by its prenatal origin, infant B-ALL (iB-ALL) shows an exceptionally silent DNA mutational landscape, suggesting that alternative epigenetic mechanisms may substantially contribute to its leukemogenesis. Here, we have integrated genome-wide DNA methylome and transcriptome data from 69 patients with de novo MLL-rearranged leukemia (MLLr) and non-MLLr iB-ALL leukemia uniformly treated according to the Interfant-99/06 protocol. iB-ALL methylome signatures display a plethora of common and specific alterations associated with chromatin states related to enhancer and transcriptional control in normal hematopoietic cells. DNA methylation, gene expression, and gene coexpression network analyses segregated MLLr away from non-MLLr iB-ALL and identified a coordinated and enriched expression of the AP-1 complex members FOS and JUN and RUNX factors in MLLr iB-ALL, consistent with the significant enrichment of hypomethylated CpGs in these genes. Integrative methylome-transcriptome analysis identified consistent cancer cell vulnerabilities, revealed a robust iB-ALL–specific gene expression–correlating dmCpG signature, and confirmed an epigenetic control of AP-1 and RUNX members in reshaping the molecular network of MLLr iB-ALL. Finally, pharmacological inhibition or functional ablation of AP-1 dramatically impaired MLLr-leukemic growth in vitro and in vivo using MLLr-iB-ALL patient–derived xenografts, providing rationale for new therapeutic avenues in MLLr-iB-ALL., We thank CERCA/Generalitat de Catalunya (SGR180) and Fundació Josep Carreras-Obra Social la Caixa for their institutional support. Financial support for this work was obtained from the European Research Council (CoG-2014-646903 and PoC-2018-811220 to PM), the Spanish Ministry of Economy and Competitiveness (SAF-2019-108160-R and SAF2016-76758-R to PM and IV, respectively), the Spanish Association against cancer (AECC-CI-2015 and PROYE18061FERN to CB and MFF), the Fundación Uno entre Cienmil (to PM), the Health Institute Carlos III (ISCIII/FEDER, PI17/01028, PI15/00892, PI18/01527 to CB and AFF/MFF, respectively). We also acknowledge the Plan de Ciencia, Tecnología e Innovación from the Asturias Government cofunding 2018–2022/FEDER (IDI/2018/146to MFF). MFF also acknowledges funding from Fundación General CSIC (0348_CIE_6_E). PM also acknowledges financial support from Fundación Leo Messi. JRT and MV are supported by Juan de la Cierva fellowships by the Spanish Ministry of Science and Innovation (FJCI-2015-26965, IJC2018-36825-I, IJCI-2017-3317) and IUOPA-ISPA-FINBA (The IUOPA is supported by the Obra Social Cajastur-Liberbank, Spain). RTR is supported by a fellowship from the AECC scientific foundation. RFP and PSO are supported by the Severo Ochoa program (BP17-114 and BP17-165, respectively)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

HDAC7 is a major contributor in the pathogenesis of infant t(4;11) proB acute lymphoblastic leukemia

  • Barrios, Oriol de
  • Galaras, Alexandros
  • Trincado, Juan L.
  • Azagra, Alba
  • Collazo, Olga
  • Meler, Ainara
  • Agraz-Doblas, Antonio
  • Bueno, Clara
  • Ballerini, Paola
  • Cazzaniga, Giovanni
  • Stam, Ronald W.
  • Varela, Ignacio
  • Lorenzo, Paola De
  • Grazia Valsecchi, Maria
  • Hatzis, Pantelis
  • Menéndez, Pablo
  • Parra, Maribel
This paper was funded by grants to MP by the Spanish Ministry of Science, Innovation and Universities (SAF2017-87990-R and EUR2019-103835) and elaborated at the Josep Carreras Leukaemia Research Institute (IJC, Badalona, Barcelona) and IDIBELL Research Institute (L’Hospitalet de Llobregat, Barcelona). OdB is funded by a Juan de la Cierva—Formación fellowship from the Spanish Ministry of Science, Innovation and Universities (FJCI-2017-32430). AM is funded by the Spanish Ministry of Science, Innovation and Universities, which is part of the Agencia Estatal de Investigación (AEI), through grant PRE2018-083183 (cofunded by the European Social Fund). Work in PM and CB’s lab was supported by the European Research Council (CoG-2014646903), the Spanish Ministry of Economy and Competitiveness (SAF-2016-80481-R), Uno entre Cien Mil Foundation, the Leo Messi Foundation, the Asociación Española Contra el Cáncer (AECC-CI-2015), and the ISCIII/FEDER (PI17/01028). ¡
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia

  • Sánchez-Martínez, Diego
  • Baroni, Matteo L.
  • Gutierrez-Agüera, Francisco
  • Roca-Ho, Heleia
  • Blanch-Lombarte, Oscar
  • González-García, Sara
  • Torrebadell, Montserrat
  • Junca, Jordi
  • Ramírez-Orellana, Manuel
  • Velasco-Hernández, Talía
  • Bueno, Clara
  • Fuster, José Luís
  • Prado, Julia G.
  • Calvo, Julien
  • Uzan, Benjamin
  • Cools, Jan
  • Camos, Mireia
  • Pflumio, Françoise
  • Toribio, María Luisa
  • Menéndez, Pablo
Relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) has a dismal outcome, and no effective targeted immunotherapies for T-ALL exist. The extension of chimeric antigen receptor (CAR) T cells (CARTs) to T-ALL remains challenging because the shared expression of target antigens between CARTs and T-ALL blasts leads to CART fratricide. CD1a is exclusively expressed in cortical T-ALL (coT-ALL), a major subset of T-ALL, and retained at relapse. This article reports that the expression of CD1a is mainly restricted to developing cortical thymocytes, and neither CD34+ progenitors nor T cells express CD1a during ontogeny, confining the risk of on-target/off-tumor toxicity. We thus developed and preclinically validated a CD1a-specific CAR with robust and specific cytotoxicity in vitro and antileukemic activity in vivo in xenograft models of coT-ALL, using both cell lines and coT-ALL patient–derived primary blasts. CD1a-CARTs are fratricide resistant, persist long term in vivo (retaining antileukemic activity in re-challenge experiments), and respond to viral antigens. Our data support the therapeutic and safe use of fratricide-resistant CD1a-CARTs for relapsed/refractory coT-ALL., This research was supported by the European Research Council (H2020) (CoG-2014-646903), the Agencia Estatal de Investigacion/European Re- ´ gional Development Fund (SAF2016-80481-R and SAF2016-75442-R), and the Catalunya Government (SGR330 and PERIS 2017) (P.M.), as well as the Asociacion Española Contra el C ´ ancer, Beca FERO, and the ´ ISCIII/FEDER (PI17/01028) (C.B.). P.M. also acknowledges institutional support from the Obra Social La Caixa-Fundacio Josep Carreras. J.G.P. ` holds a Miguel Servet contract (CP15/00014), and O.B.-L. is supported by an AGAUR-FI fellowship from the Catalan Government. P.M. is an investigator of the Spanish Cell Therapy cooperative network (TERCEL)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Loss of 5hmC identifies a new type of aberrant DNA hypermethylation in glioma

  • Fernández, Agustín F.
  • Bayón, Gustavo F.
  • Sierra, Marta I.
  • Urdinguio, Rocío G.
  • Toraño, Estela G.
  • García, María G.
  • Carella, Antonella
  • López, Virginia
  • Santamarina-Ojeda, Pablo
  • Pérez, Raúl F.
  • Belmonte, Thalia
  • Tejedor, Juan Ramón
  • Cobo, Isabel
  • Menéndez, Pablo
  • Mangas, Cristina
  • Ferrero, Cecilia
  • Rodrigo, Luis
  • Astudillo, Aurora
  • Ortea, Ignacio
  • Mollejo, Manuela
  • Meléndez, Bárbara
  • Fraga, Mario F.
Aberrant DNA hypermethylation is a hallmark of cancer although the underlying molecular mechanisms are still poorly understood. To study the possible role of 5-hydroxymethylcytosine (5hmC) in this process we analyzed the global and locus-specific genome-wide levels of 5hmC and 5-methylcytosine (5mC) in human primary samples from 12 non-tumoral brains and 53 gliomas. We found that the levels of 5hmC identified in non-tumoral samples were significantly reduced in gliomas. Strikingly, hypo-hydroxymethylation at 4627 (9.3%) CpG sites was associated with aberrant DNA hypermethylation and was strongly enriched in CpG island shores. The DNA regions containing these CpG sites were enriched in H3K4me2 and presented a different genuine chromatin signature to that characteristic of the genes classically aberrantly hypermethylated in cancer. As this 5mC gain is inversely correlated with loss of 5hmC and has not been identified with classical sodium bisulfite-based technologies, we conclude that our data identifies a novel 5hmC-dependent type of aberrant DNA hypermethylation in glioma., This work has been financially supported by: the Plan Nacional de I+D+I 2013–2016/FEDER (PI15/00892 to M.F.F. and A.F.F.; RTC-2015-3393-1 to A.F.F.); the ISCIII-Subdirección General de Evaluación y Fomento de la Investigación, and the Plan Nacional de I+D+I 2008–2011/FEDER (CP11/00131 to A.F.F.); IUOPA (to G.F.B. and M.S); the Fundación Científica de la AECC (to R.G.U.); the Fundación Ramón Areces (to M.F.F); FICYT (to E.G.T., M.G.G. and A.C.); and the Asturias Regional Government (GRUPIN14-052 to M.F.F.). Work in P.M. laboratory is supported by the European Research Council (CoG-2014-646903), the Spanish Ministry of Economy-Competitiveness (SAF-SAF2013-43065), the Obra Social La Caixa-Fundaciò Josep Carreras, and the Generalitat de Catalunya. P.M. is an investigator in the Spanish Cell Therapy cooperative network (TERCEL). The IUOPA is supported by the Obra Social Cajastur-Liberbank, Spain., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

GATA2 Promotes Hematopoietic Development and Represses Cardiac Differentiation of Human Mesoderm

  • Castaño, Julio
  • Aranda, Sergi
  • Bueno, Clara
  • Calero-Nieto, Fernando J.
  • Mejia-Ramirez, Eva
  • Mosquera Mayo, José Luís
  • Blanco, Enrique
  • Wang, Xiaonan
  • Prieto Rios, Cristina
  • Zabaleta, Lorea
  • Mereu, Elisabetta
  • Rovira, Meritxell
  • Jiménez-Delgado, Senda
  • Matson, Daniel R.
  • Heyn, Holger
  • Bresnick, Emery H.
  • Göttgens, Berthold
  • Di Croce, Luciano
  • Menéndez Buján, Pablo
  • Raya Chamorro, Ángel
  • Giorgetti, Alessandra
In vertebrates, GATA2 is a master regulator of hematopoiesis and is expressed throughout embryo development and in adult life. Although the essential role of GATA2 in mouse hematopoiesis is well established, its involvement during early human hematopoietic development is not clear. By combining time-controlled overexpression of GATA2 with genetic knockout experiments, we found that GATA2, at the mesoderm specification stage, promotes the generation of hemogenic endothelial progenitors and their further differentiation to hematopoietic progenitor cells, and negatively regulates cardiac differentiation. Surprisingly, genome-wide transcriptional and chromatin immunoprecipitation analysis showed that GATA2 bound to regulatory regions, and repressed the expression of cardiac development-related genes. Moreover, genes important for hematopoietic differentiation were upregulated by GATA2 in a mostly indirect manner. Collectively, our data reveal a hitherto unrecognized role of GATA2 as a repressor of cardiac fates, and highlight the importance of coordinating the specification and repression of alternative cell fates.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL

  • Prieto, Cristina
  • Iglesias Coma, Mar
  • Menéndez, Pablo
Mixed-lineage leukemia (MLL)-rearranged (MLLr) infant B-cell acute lymphoblastic leukemia (iMLLr-B-ALL) has a dismal prognosis and is associated with a pro-B/mixed phenotype, therapy refractoriness and frequent central nervous system (CNS) disease/relapse. Neuron-glial antigen 2 (NG2) is specifically expressed in MLLr leukemias and is used in leukemia immunophenotyping because of its predictive value for MLLr acute leukemias. NG2 is involved in melanoma metastasis and brain development; however, its role in MLL-mediated leukemogenesis remains elusive. Here we evaluated whether NG2 distinguishes leukemia-initiating/propagating cells (L-ICs) and/or CNS-infiltrating cells (CNS-ICs) in iMLLr-B-ALL. Clinical data from the Interfant cohort of iMLLr-B-ALL demonstrated that high NG2 expression associates with lower event-free survival, higher number of circulating blasts and more frequent CNS disease/relapse. Serial xenotransplantation of primary MLL-AF4+ leukemias indicated that NG2 is a malleable marker that does not enrich for L-IC or CNS-IC in iMLLr-B-All. However, NG2 expression was highly upregulated in blasts infiltrating extramedullar hematopoietic sites and CNS, and specific blockage of NG2 resulted in almost complete loss of engraftment. Indeed, gene expression profiling of primary blasts and primografts revealed a migratory signature of NG2+ blasts. This study provides new insights on the biology of NG2 in iMLLr-B-ALL and suggests NG2 as a potential therapeutic target to reduce the risk of CNS disease/relapse and to provide safer CNS-directed therapies for iMLLr-B-ALL., This work was supported by the European Research Council (CoG-2014-646903) and the Spanish Ministry of Economy-Competitiveness (SAF-SAF2013-43065) to PM, the Asociación Española Contra el Cáncer to CB and the ISCIII/FEDER (PI14/01191-PI13/00168) to CB and JCRM. PM acknowledges the financial support from the Obra Social La Caixa-Fundaciò Josep Carreras, the Inocente-Inocente Foundation and Generalitat de Catalunya. CP and DRM were funded by PFIS scholarships from the ISCIII. VA has financial support from L’Oreal-UNESCO. PM is investigator of the Spanish Cell Therapy cooperative network (TERCEL). We thank Antonio Agraz/Ignacio Varela (IBBTEC, Santander) for assisting in microarray analysis. We also thank Dr Patricia Pérez-Galán and Gael Roue (IDIBAPS, Barcelona, Spain) for helpful discussions on NG2 blocking experiments.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis

  • Agraz-Doblas, Antonio
  • Bueno, Clara
  • Bashford-Rogers, Rachael
  • Roy, Anindita
  • Schneider, Pauline
  • Bardini, Michela
  • Ballerini, Paola
  • Cazzaniga, Gianni
  • Moreno, Thaidy
  • Revilla, Carlos
  • Gut, Marta
  • Valsecchi, Maria G.
  • Roberts, Irene
  • Pieters, Rob
  • De Lorenzo, Paola
  • Varela, Ignacio
  • Menéndez, Pablo
  • Stam, Ronald W.
B-cell acute lymphoblastic leukemia is the commonest childhood cancer. In infants, B-cell acute lymphoblastic leukemia remains fatal, especially in patients with t(4;11), present in ~80% of cases. The pathogenesis of t(4;11)/KMT2A-AFF1+ (MLL-AF4+) infant B-cell acute lymphoblastic leukemia remains difficult to model, and the pathogenic contribution in cancer of the reciprocal fusions resulting from derivative translocated-chromosomes remains obscure. Here, "multi-layered" genome-wide analyses and validation were performed on a total of 124 de novo cases of infant B-cell acute lymphoblastic leukemia uniformly diagnosed and treated according to the Interfant 99/06 protocol. These patients showed the most silent mutational landscape reported so far for any sequenced pediatric cancer. Recurrent mutations were exclusively found in K-RAS and N-RAS, were subclonal and were frequently lost at relapse, despite a larger number of non-recurrent/non-silent mutations. Unlike non-MLL-rearranged B-cell acute lymphoblastic leukemias, B-cell receptor repertoire analysis revealed minor, non-expanded B-cell clones in t(4;11)+ infant B-cell acute lymphoblastic leukemia, and RNA-sequencing showed transcriptomic similarities between t(4;11)+ infant B-cell acute lymphoblastic leukemias and the most immature human fetal liver hematopoietic stem and progenitor cells, confirming a "pre-VDJ" fetal cellular origin for both t(4;11) and RAS mut The reciprocal fusion AF4-MLL was expressed in only 45% (19/43) of the t(4;11)+ patients, and HOXA cluster genes are exclusively expressed in AF4-MLL-expressing patients. Importantly, AF4-MLL/HOXA-expressing patients had a significantly better 4-year event-free survival (62.4% vs 11.7%, P=0.001), and overall survival (73.7 vs 25.2%, P=0.016). AF4-MLL expression retained its prognostic significance when analyzed in a Cox model adjusting for risk stratification according to the Interfant-06 protocol based on age at diagnosis, white blood cell count and response to prednisone. This study has clinical implications for disease outcome and diagnostic risk-stratification of t(4;11)+ infant B-cell acute lymphoblastic leukemia., The human fetal material was provided by the Joint MRC/Wellcome Trust (grant# MR/R006237/1) Human Developmental Biology Resource (http://hdbr.org). This work was supported by the European Research Council (CoG-2014-646903 to PM; and StG-2014-637904 to IV), the Spanish Ministry of Economy and Competitiveness (SAF-SAF2013-43065 to PM and SAF2016-76758-R to IV), the Asociación Española Contra el Cáncer (AECC-CI-2015), FERO Foundation, and the ISCIII (PI14-01191) to CB. PM/IV also acknowledge financial support from The Obra Social La Caixa-Fundaciò Josep Carreras, The Inocente Inocente Foundation, Fundación Ramón Areces and The Generalitat de Catalunya (SGR330). IR was supported by a Programme Grant from Bloodwise (LLR 13001). PM is an investigator of the Spanish Cell Therapy cooperative network (TERCEL). AR was supported by a Clinician Scientist Fellowship from Bloodwise (14041)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Development of a novel anti-CD19 chimeric antigen receptor: A paradigm for an affordable CAR T cell production at academic institutions

  • Castellà Castellà, Maria
  • Boronat, Anna
  • Martín Ibáñez, Raquel
  • Rodríguez, Vanina
  • Suñé, Guillermo
  • Caballero, Miguel
  • Marzal Martí, Berta
  • Pérez-Amill, Lorena
  • Martín-Antonio, Beatriz
  • Castaño, Julio
  • Bueno, Clara
  • Balagué, Olga
  • González Navarro, E. Azucena
  • Serra Pagès, Carles
  • Engel Rocamora, Pablo
  • Vilella, Ramon
  • Benítez-Ribas, Daniel
  • Ortiz-Maldonado Gibson, Valentín
  • Cid Vidal, Joan
  • Tabera, Jaime
  • Canals i Coll, Josep M.
  • Lozano, Miquel
  • Baumann, Tycho
  • Vilarrodona, Anna
  • Trias, Esteve
  • Campo Güerri, Elias
  • Menéndez Buján, Pablo
  • Urbano Ispizua, Álvaro
  • Yagüe, Jordi
  • Pérez Galán, Patricia
  • Rives Solà, Susana
  • Delgado, Julio (Delgado González)
  • Juan, Manel
Genetically modifying autologous T cells to express an anti-CD19 chimeric antigen receptor (CAR) has shown impressive response rates for the treatment of CD19+ B cell malignancies in several clinical trials (CTs). Making this treatment available to our patients prompted us to develop a novel CART19 based on our own anti-CD19 antibody (A3B1), followed by CD8 hinge and transmembrane region, 4-1BB- and CD3z-signaling domains. We show that A3B1 CAR T cells are highly cytotoxic and specific against CD19+ cells in vitro, inducing secretion of pro-inflammatory cytokines and CAR T cell proliferation. In vivo, A3B1 CAR T cells are able to fully control disease progression in an NOD.Cg-Prkdcscid Il2rdtm1Wjl/SzJ (NSG) xenograph B-ALL mouse model. Based on the pre-clinical data, we conclude that our CART19 is clearly functional against CD19+ cells, to a level similar to other CAR19s currently being used in the clinic. Concurrently, we describe the implementation of our CAR T cell production system, using lentiviral vector and CliniMACS Prodigy, within a medium-sized academic institution. The results of the validation phase show our system is robust and reproducible, while maintaining a low cost that is affordable for academic institutions. Our model can serve as a paradigm for similar institutions, and it may help to make CAR T cell treatment available to all patients.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Robustness of catalytically dead Cas9 activators in human pluripotent and mesenchymal stem cells

  • Petazzi, Paolo
  • Torres-Ruiz, Raul
  • Fidanza, Antonella
  • Roca-Ho, Heleia
  • Gutierrez-Agüera, Francisco
  • Castaño, Julio
  • Rodríguez-Perales, Sandra
  • Diaz de la Guardia, Rafael
  • López-Millán, Belén
  • Bigas Salvans, Anna
  • Forrester, Lesley M.
  • Bueno, Clara
  • Menéndez, Pablo
Human pluripotent stem cells (hPSCs) and mesenchymal stromal/stem cells (hMSCs) are clinically relevant sources for cellular therapies and for modeling human development and disease. Many stem cell-based applications rely on the ability to activate several endogenous genes simultaneously to modify cell fate. However, genetic intervention of these cells remains challenging. Several catalytically dead Cas9 (dCas9) proteins fused to distinct activation domains can modulate gene expression when directed to their regulatory regions by a specific single-guide RNA (sgRNA). In this study, we have compared the ability of the first-generation dCas9-VP64 activator and the second-generation systems, dCas9-SAM and dCas9-SunTag, to induce gene expression in hPSCs and hMSCs. Several stem cell lines were tested for single and multiplexed gene activation. When the activation of several genes was compared, all three systems induced specific and potent gene expression in both single and multiplexed settings, but the dCas9-SAM and dCas9-SunTag systems resulted in the highest and most consistent level of gene expression. Simultaneous targeting of the same gene with multiple sgRNAs did not result in additive levels of gene expression in hPSCs nor hMSCs. We demonstrate the robustness and specificity of second-generation dCas9 activators as tools to simultaneously activate several endogenous genes in clinically relevant human stem cells., We thank CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for their institutional support. We thank Jose Luis Sardina (IJC, Barcelona) for technical assistance with the teratoma assays. Financial support for this work was obtained from the Catalunya Goverment (SGR330 and PERIS 2017-2019), the Spanish Ministry of Economy and Competitiveness (SAF2016-80481-R), the European Research Council (CoG-2014-646903), and the Fundación Leo Messi to P.M.; the Spanish Association against Cancer (AECC-CI-2015) and the Health Institute Carlos III (ISCIII/FEDER, PI17/01028) to C.B.; the Biotechnology and Biological Sciences Research Council (BBRSC) to L.M.F. and A.F.; and the Spanish National Research and Development Plan (ISCIII/FEDER, PI17/02303) and the AEI/MICIU EXPLORA Project (BIO2017-91272-EXP) to S.R.-P. P.M. is an investigator of the Spanish Cell Therapy Cooperative Network (TERCEL). R.T.-R. is supported by a postdoctoral fellowship from the Asociación Española Contra el Cáncer (AECC).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment

  • Urdinguio, Rocío G.
  • Lopez, Virginia
  • Bayón, Gustavo F.
  • Diaz de la guardia, Rafael
  • Sierra, Marta I.
  • García Toraño, Estela
  • Perez, Raúl F.
  • García, María G.
  • Carella, Antonella
  • Pruneda, Patricia C.
  • Prieto, Cristina
  • Dmitrijeva, Marija
  • Santamarina, Pablo
  • Belmonte, Thalía
  • Mangas, Cristina
  • Diaconu, Elena
  • Ferrero, Cecilia
  • Tejedor, Juan Ramón
  • Fernandez Morera, Juan Luis
  • Bravo, Cristina
  • Bueno, Clara
  • Sanjuan Pla, Alejandra
  • Rodriguez, Ramon M.
  • Suarez Alvarez, Beatriz
  • López Larrea, Carlos
  • Bernal, Teresa
  • Colado, Enrique
  • Balbín, Milagros
  • García Suarez, Olivia
  • Chiara, María Dolores
  • Sáenz de Santa María, Inés
  • Rodríguez, Francisco
  • Pando Sandoval, Ana
  • Rodrigo, Luis
  • Santos, Laura
  • Salas, Anna
  • Vallejo Díaz, Jesús
  • Carrera, Ana C.
  • Rico, Daniel
  • Hernández López, Inmaculada
  • Vayá, Amparo
  • Ricart, Josep M.
  • Seto, Edward
  • Sima Teruel, Núria
  • Vaquero García, Alejandro
  • Valledor, Luis
  • Cañal, Maria Jesus
  • Pisano, David
  • Graña Castro, Osvaldo
  • Thomas, Tim
  • Voss, Anne K.
  • Menéndez, Pablo
  • Villar Garea, Ana
  • Deutzmann, Rainer
  • Fernandez, Agustín F.
  • Fraga, Mario F.
Histone H4 acetylation at Lysine 16 (H4K16ac) is a key epigenetic mark involved in gene regulation, DNA repair and chromatin remodeling, and though it is known to be essential for embryonic development, its role during adult life is still poorly understood. Here we show that this lysine is massively hyperacetylated in peripheral neutrophils. Genome-wide mapping of H4K16ac in terminally differentiated blood cells, along with functional experiments, supported a role for this histone post-translational modification in the regulation of cell differentiation and apoptosis in the hematopoietic system. Furthermore, in neutrophils, H4K16ac was enriched at specific DNA repeats. These DNA regions presented an accessible chromatin conformation and were associated with the cleavage sites that generate the 50 kb DNA fragments during the first stages of programmed cell death. Our results thus suggest that H4K16ac plays a dual role in myeloid cells as it not only regulates differentiation and apoptosis, but it also exhibits a non-canonical structural role in poising chromatin for cleavage at an early stage of neutrophil cell death.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens

  • Vidal Crespo, Anna
  • Matas Céspedes, Alba
  • Rodríguez, Vanina
  • Rossi, Cédric
  • Valero, Juan G.
  • Serrat Aymerich, Neus
  • Sanjuan Pla, Alejandra
  • Menéndez Buján, Pablo
  • Roué, Gaël
  • López Guillermo, Armando
  • Giné Soca, Eva
  • Campo Güerri, Elias
  • Colomer Pujol, Dolors
  • Bezombes, Christine
  • Lammerts van Bueren, J.
  • Chiu, Christopher
  • Doshi, Parul
  • Pérez Galán, Patricia
CD38 is expressed in several types of non-Hodgkin lymphoma and constitutes a promising target for antibody-based therapy. Daratumumab (Darzalex) is a first-in-class anti-CD38 antibody approved for the treatment of relapsed/refractory multiple myeloma. It has also demonstrated clinical activity in Waldenstrom macroglobulinaemia and amyloidosis. Here, we have evaluated the activity and mechanism of action of daratumumab in preclinical in vitro and in vivo models of mantle cell lymphoma, follicular lymphoma and diffuse large B cell lymphoma, as monotherapy or in combination with standard chemo-immunotherapy. In vitro, daratumumab engages Fc-mediated cytotoxicity by antibody-dependent cell cytotoxicity and antibody-dependent cell phagocytosis in all lymphoma subtypes. In the presence of human serum, complement-dependent cell cytotoxicity was marginally engaged. We demonstrated by Selective Plane Illumination Microscopy that daratumumab fully penetrated a 3D lymphoma organoid and decreased organoid volume. In vivo, daratumumab completely prevents tumor outgrowth in models of mantle cell and follicular lymphoma, and shows comparable activity to rituximab in a disseminated in vivo model of blastic mantle cell lymphoma. Moreover, daratumumab improves overall survival in a mouse model of transformed CD20dim follicular lymphoma, where rituximab showed limited activity. Daratumumab potentiates the antitumor activity of CHOP and R-CHOP in mantle cell and follicular lymphoma xenografts. Furthermore, in a patient-derived diffuse large B cell lymphoma xenograft model, daratumumab anti-tumor activity was comparable to R-CHOP and the addition of daratumumab to either CHOP or R-CHOP led to full tumor regression. In summary, daratumumab constitutes a novel therapeutic opportunity in certain scenarios and these results warrant further clinical development.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Developmental refractoriness of MLL-rearranged human B-cell acute leukemias to reprogramming into pluripotency

  • Muñoz, Alvaro
  • Romero Moya, Damià
  • Prieto, Cristina
  • Ramos-Mejía, Verónica
  • Agraz-Doblas, Antonio
  • Varela, Ignacio
  • Buschbeck, Marcus
  • Palau de Miguel, Anna
  • Carvajal-Vergara, Xonia
  • Giorgetti, Alessandra
  • Ford, Anthony
  • Lako, Majlinda
  • Granada, Isabel
  • Ruiz-Xivillé, Neus
  • Rodríguez-Perales, Sandra
  • Torres-Ruíz, Raul
  • Stam, Ronald W.
  • Fuster, Jose Luis
  • Fraga, Mario F.
  • Nakanishi, Mahito
  • Cazzaniga, Gianni
  • Bardini, Michela
  • Cobo, Isabel
  • Bayón, Gustavo F.
  • Fernández, Agustín F.
  • Bueno, Clara
  • Menéndez Buján, Pablo
Induced pluripotent stem cells (iPSCs) are a powerful tool for disease modeling. They are routinely generated from healthy donors and patients from multiple cell types at different developmental stages. However, reprogramming leukemias is an extremely inefficient process. Few studies generated iPSCs from primary chronic myeloid leukemias, but iPSC generation from acute myeloid or lymphoid leukemias (ALL) has not been achieved. We attempted to generate iPSCs from different subtypes of B-ALL to address the developmental impact of leukemic fusion genes. OKSM(L)-expressing mono/polycistronic-, retroviral/lentiviral/episomal-, and Sendai virus vector-based reprogramming strategies failed to render iPSCs in vitro and in vivo. Addition of transcriptomic-epigenetic reprogramming 'boosters' also failed to generate iPSCs from B cell blasts and B-ALL lines, and when iPSCs emerged they lacked leukemic fusion genes, demonstrating non-leukemic myeloid origin. Conversely, MLL-AF4-overexpressing hematopoietic stem cells/B progenitors were successfully reprogrammed, indicating that B cell origin and leukemic fusion gene were not reprogramming barriers. Global transcriptome/DNA methylome profiling suggested a developmental/differentiation refractoriness of MLL-rearranged B-ALL to reprogramming into pluripotency.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Proinflammatory signals are insufficient to drive definitive hematopoietic specification of human HSCs in vitro

  • Giorgetti, Alessandra
  • Castaño, Julio
  • Bueno, Clara
  • Diaz de la Guardia, Rafael
  • Delgado, Mario
  • Bigas Salvans, Anna
  • Espinosa, Lluís
  • Menéndez Buján, Pablo
Recent studies in zebrafish and mice have revealed that proinflammatory signaling is a positive regulator of definitive hematopoietic development. Whether proinflammatory signaling also regulates human hematopoietic specification remains unknown. Here, we explored the impact of the proinflammatory cytokines tumor necrosis factor-α (TNFα), interferon-γ (IFNγ), and interleukin-1β (IL1β) on in vitro hematopoietic differentiation using human pluripotent stem cells. Gene expression analysis and enzyme-linked immunosorbent assay revealed the absence of a proinflammatory signature during hematopoietic development of human pluripotent stem cells. Functionally, the emergence of hemogenic endothelial progenitors (CD31+CD34+CD45− or CD34+CD43−CD73−) and hematopoietic cells (CD43+CD45+) was not affected by treatment with increasing doses of TNFα, IFNγ, and IL1β irrespective of the developmental window or the differentiation protocol used (embryoid body or OP9 co-culture based). Similarly, knockdown of endogenous NF-kB signaling had no impact on hematopoietic differentiation of human pluripotent stem cells. This study serves as a demonstration that TNFα, IFNγ, and IL1β signals do not improve hematopoietic differentiation of human pluripotent stem cells using current protocols and suggests that proinflammatory signaling is insufficient to drive definitive hematopoietic specification of human hematopoietic stem cells in vitro.
Docta Complutense
Publication Artículo científico (JournalArticle)

Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment

  • Urdinguio, Rocío G.
  • Lopez, Virginia
  • Bayón, Gustavo F.
  • Diaz de la Guardia, Rafael
  • Sierra, Marta I.
  • García Toraño, Estela
  • Perez, Raúl F
  • García, María G.
  • Carella, Antonella
  • Pruneda, Patricia C.
  • Prieto, Cristina
  • Dmitrijeva, Marija
  • Santamarina, Pablo
  • Belmonte, Thalía
  • Mangas, Cristina
  • Diaconu, Elena
  • Ferrero, Cecilia
  • Tejedor, Juan Ramón
  • Fernandez Morera, Juan Luis
  • Bravo, Cristina
  • Bueno, Clara
  • Sanjuan Pla, Alejandra
  • Rodriguez, Ramón M.
  • Suarez Alvarez, Beatriz
  • López Larrea, Carlos
  • Bernal, Teresa
  • Colado, Enrique
  • Balbín, Milagros
  • García Suarez, Olivia
  • Chiara, Maria Dolores
  • Sáenz de Santa María, Inés
  • Rodríguez, Francisco
  • Pando Sandoval, Ana
  • Rodrigo, Luis
  • Santos, Laura
  • Salas, Ana
  • Vallejo Díaz, Jesús
  • Carrera, Ana C.
  • Rico, Daniel
  • Hernández López, Inmaculada
  • Vayá, Amparo
  • Ricart, José M.
  • Seto, Edward
  • Sima Teruel, Núria
  • Vaquero, Alejandro
  • Valledor, Luis
  • Cañal, Maria Jesus
  • Pisano, David
  • Graña Castro, Osvaldo
  • Thomas, Tim
  • Voss, Anne K.
  • Menéndez, Pablo
  • Villar Garea, Ana
  • Deutzmann, Rainer
  • Fernandez, Agustín F.
  • Fraga, Mario F.
Histone H4 acetylation at Lysine 16 (H4K16ac) is a key epigenetic mark involved in gene regulation, DNA repair and chromatin remodeling, and though it is known to be essential for embryonic development, its role during adult life is still poorly understood. Here we show that this lysine is massively hyperacetylated in peripheral neutrophils. Genome-wide mapping of H4K16ac in terminally differentiated blood cells, along with functional experiments, supported a role for this histone post-translational modification in the regulation of cell differentiation and apoptosis in the hematopoietic system. Furthermore, in neutrophils, H4K16ac was enriched at specific DNA repeats. These DNA regions presented an accessible chromatin conformation and were associated with the cleavage sites that generate the 50 kb DNA fragments during the first stages of programmed cell death. Our results thus suggest that H4K16ac plays a dual role in myeloid cells as it not only regulates differentiation and apoptosis, but it also exhibits a non-canonical structural role in poising chromatin for cleavage at an early stage of neutrophil cell death.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency

  • Muñoz López, Álvaro|||0000-0002-4601-5633
  • Romero Moya, Damià|||0000-0001-9947-3577
  • Prieto, Cristina|||0000-0002-0812-8100
  • Ramos Mejía, Verónica
  • Agraz-Doblás, Antonio|||0000-0003-1307-4175
  • Varela, Ignacio|||0000-0002-0969-506X
  • Buschbeck, Marcus|||0000-0002-3218-4567
  • Palau de Miguel, Anna|||0000-0003-2131-1265
  • Carvajal Vergara, Xonia
  • Giorgetti, Alessandra|||0000-0001-5803-3567
  • Ford, Anthony
  • Lako, Majlinda
  • Granada, Isabel|||0000-0002-4275-0104
  • Ruiz Xivillé, Neus
  • Rodríguez Perales, Sandra
  • Torres Ruíz, Raúl
  • Stam, Ronald W.
  • Fuster, José Luis|||0000-0002-4881-9440
  • Fraga, Mario|||0000-0001-8450-2603
  • Nakanishi, Mahito
  • Cazzaniga, Giovanni|||0000-0003-2955-4528
  • Bardini, Michela|||0000-0002-6942-2274
  • Cobo, Isabel
  • Fernández Bayón, Gustavo|||0000-0002-0763-0473
  • Fernández, Agustín F.|||0000-0002-3792-4085
  • Bueno, Clara|||0000-0003-1442-6216
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Induced pluripotent stem cells (iPSCs) are a powerful tool for disease modeling. They are routinely generated from healthy donors and patients from multiple cell types at different developmental stages. However, reprogramming leukemias is an extremely inefficient process. Few studies generated iPSCs from primary chronic myeloid leukemias, but iPSC generation from acute myeloid or lymphoid leukemias (ALL) has not been achieved. We attempted to generate iPSCs from different subtypes of B-ALL to address the developmental impact of leukemic fusion genes. OKSM(L)-expressing mono/polycistronic-, retroviral/lentiviral/episomal-, and Sendai virus vector-based reprogramming strategies failed to render iPSCs in vitro and in vivo. Addition of transcriptomic-epigenetic reprogramming "boosters" also failed to generate iPSCs from B cell blasts and B-ALL lines, and when iPSCs emerged they lacked leukemic fusion genes, demonstrating non-leukemic myeloid origin. Conversely, MLL-AF4-overexpressing hematopoietic stem cells/B progenitors were successfully reprogrammed, indicating that B cell origin and leukemic fusion gene were not reprogramming barriers. Global transcriptome/DNA methylome profiling suggested a developmental/differentiation refractoriness of MLL-rearranged B-ALL to reprogramming into pluripotency.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes

  • Díaz de la Guardia, Rafael|||0000-0001-9568-6719
  • López-Millán, Belén|||0000-0002-9757-5454
  • Lavoie, Jessie R.
  • Bueno, Clara|||0000-0003-1442-6216
  • Castaño Cardoso, Julio|||0000-0002-0712-5856
  • Gómez-Casares, Maite
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Palomo Sanchís, Laura|||0000-0003-3176-6271
  • Juan, Manel|||0000-0002-3064-1648
  • Delgado, Julio|||0000-0002-5157-4376
  • Blanco, Maria L.
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Chaparro, Alberto
  • Fuster, José Luis|||0000-0002-4881-9440
  • Anguita, Eduardo|||0000-0003-1386-4943
  • Rosu-Myles, Michael
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Bone marrow mesenchymal stem/stromal cells (BM-MSCs) are key components of the hematopoietic niche thought to have a direct role in leukemia pathogenesis. BM-MSCs from patients with acute myeloid leukemia (AML) have been poorly characterized due to disease heterogeneity. We report a functional, genetic, and immunological characterization of BM-MSC cultures from 46 AML patients, stratified by molecular/cytogenetics into low-risk (LR), intermediate-risk (IR), and high-risk (HR) subgroups. Stable MSC cultures were successfully established and characterized from 40 of 46 AML patients irrespective of the risk subgroup. AML-derived BM-MSCs never harbored tumor-specific cytogenetic/molecular alterations present in blasts, but displayed higher clonogenic potential than healthy donor (HD)-derived BM-MSCs. Although HD- and AML-derived BM-MSCs equally provided chemoprotection to AML cells in vitro, AML-derived BM-MSCs were more immunosuppressive/anti-inflammatory, enhanced suppression of lymphocyte proliferation, and diminished secretion of pro-inflammatory cytokines. Multivariate analysis revealed that the level of interleukin-10 produced by AML-derived BM-MSCs as an independent prognostic factor negatively affected overall survival. Collectively our data show that AML-derived BM-MSCs are not tumor related, but display functional differences contributing to therapy resistance and disease evolution. In this article, Díaz de la Guardia and colleagues report a functional, genetic, and immunological characterization of BM-MSC cultures from 46 AML patients, stratified by molecular/cytogenetics into low-risk (LR), intermediate-risk (IR), and high-risk (HR) subgroups. BM-MSCs never harbored tumor-specific cytogenetic/molecular alterations present in blasts, and IL-10 produced by AML-derived BM-MSCs is an independent prognostic factor negatively impacting on overall survival.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

H3K79me2/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells

  • Godfrey, Laura|||0000-0002-6222-3563
  • Crump, Nicholas|||0000-0001-9610-6763
  • O'Byrne, Sorcha|||0000-0002-3116-1646
  • Lau, I. Jun
  • Rice, Siobhan
  • Harman, Joe R.
  • Jackson, Thomas
  • Elliott, Natalina|||0000-0002-6713-7349
  • Buck, Gemma
  • Connor, Christopher
  • Thorne, Ross
  • Knapp, David J. H. F.
  • Heidenreich, Olaf|||0000-0001-5404-6483
  • Vyas, Paresh
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Inglott, Sara
  • Ancliff, Philip
  • Geng, Huimin
  • Roberts, Irene|||0000-0002-6094-6397
  • Roy, Anindita
  • Milne, Thomas|||0000-0002-0413-4271
MLL gene rearrangements (MLLr) are a common cause of aggressive, incurable acute lymphoblastic leukemias (ALL) in infants and children, most of which originate in utero. The most common MLLr produces an MLL-AF4 fusion protein. MLL-AF4 promotes leukemogenesis by activating key target genes, mainly through recruitment of DOT1L and increased histone H3 lysine-79 methylation (H3K79me2/3). One key MLL-AF4 target gene is PROM1, which encodes CD133 (Prominin-1). CD133 is a pentaspan transmembrane glycoprotein that represents a potential pan-cancer target as it is found on multiple cancer stem cells. Here we demonstrate that aberrant PROM1/CD133 expression is essential for leukemic cell growth, mediated by direct binding of MLL-AF4. Activation is controlled by an intragenic H3K79me2/3 enhancer element (KEE) leading to increased enhancer-promoter interactions between PROM1 and the nearby gene TAPT1. This dual locus regulation is reflected in a strong correlation of expression in leukemia. We find that in PROM1/CD133 non-expressing cells, the PROM1 locus is repressed by polycomb repressive complex 2 (PRC2) binding, associated with reduced expression of TAPT1, partially due to loss of interactions with the PROM1 locus. Together, these results provide the first detailed analysis of PROM1/CD133 regulation that explains CD133 expression in MLLr ALL.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope

  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • Zanetti, S. R.|||0000-0002-9052-8751
  • Roca Ho, Heleia|||0000-0001-7324-5234
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Petazzi, Paolo|||0000-0002-1036-2895
  • Sánchez Martínez, Diego|||0000-0003-4605-5325
  • Molina, Oscar|||0000-0001-7585-4519
  • Baroni, Matteo Libero|||0000-0001-8265-2050
  • Fuster, José Luis|||0000-0002-4881-9440
  • Ballerini, Paola
  • Bueno, Clara|||0000-0003-1442-6216
  • Fernández-Fuentes, Narcís
  • Engel, Pablo|||0000-0001-8410-252X
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Background There are few therapeutic options available for patients with B-cell acute lymphoblastic leukemia (B-ALL) relapsing as CD19 - either after chemotherapy or CD19-targeted immunotherapies. CD22-chimeric antigen receptor (CAR) T cells represent an attractive addition to CD19-CAR T cell therapy because they will target both CD22 + CD19 - B-ALL relapses and CD19 - preleukemic cells. However, the immune escape mechanisms from CD22-CAR T cells, and the potential contribution of the epitope binding of the anti-CD22 single-chain variable fragment (scFv) remain understudied. Methods Here, we have developed and comprehensively characterized a novel CD22-CAR (clone hCD22.7) targeting a membrane-distal CD22 epitope and tested its cytotoxic effects against B-ALL cells both in in vitro and in vivo assays. Results Conformational epitope mapping, cross-blocking, and molecular docking assays revealed that the hCD22.7 scFv is a high-affinity binding antibody which specifically binds to the ESTKDGKVP sequence, located in the Ig-like V-type domain, the most distal domain of CD22. We observed efficient killing of B-ALL cells in vitro, although the kinetics were dependent on the level of CD22 expression. Importantly, we show an efficient in vivo control of patients with B-ALL derived xenografts with diverse aggressiveness, coupled to long-term hCD22.7-CAR T cell persistence. Remaining leukemic cells at sacrifice maintained full expression of CD22, ruling out CAR pressure-mediated antigen loss. Finally, the immunogenicity capacity of this hCD22.7-scFv was very similar to that of other CD22 scFv previously used in adoptive T cell therapy. Conclusions We report a novel, high-affinity hCD22.7 scFv which targets a membrane-distal epitope of CD22. 4-1BB-based hCD22.7-CAR T cells efficiently eliminate clinically relevant B- CD22 high and CD22 low ALL primary samples in vitro and in vivo. Our study supports the clinical translation of this hCD22.7-CAR as either single or tandem CD22-CD19-CAR for both naive and anti-CD19-resistant patients with B-ALL.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity

  • Zanetti, S. R.|||0000-0002-9052-8751
  • Romecín, Paola Alejandra|||0000-0001-6890-5883
  • Vinyoles, Meritxell|||0000-0003-1906-4701
  • Juan, Manel|||0000-0002-3064-1648
  • Fuster, José Luis|||0000-0002-4881-9440
  • Camós, Mireia|||0000-0003-3658-7942
  • Querol, Sergi|||0000-0002-1105-8633
  • Delgado, M.
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Background Although adoptive transfer of CD19-directed chimeric antigen receptor (CAR) T-cells (CD19-CAR T-cells) achieves high rates of complete response in patients with B-cell acute lymphoblastic leukemia (B-ALL), relapse is common. Bone marrow (BM) mesenchymal stem/stromal cells (BM-MSC) are key components of the hematopoietic niche and are implicated in B-ALL pathogenesis and therapy resistance. MSC exert an immunosuppressive effect on T-cells; however, their impact on CD19-CAR T-cell activity is understudied. Methods We performed a detailed characterization of BM-MSC from pediatric patients with B-ALL (B-ALL BM-MSC), evaluated their immunomodulatory properties and their impact on CD19-CAR T-cell activity in vitro using microscopy, qRT-PCR, ELISA, flow cytometry analysis and in vivo using a preclinical model of severe colitis and a B-ALL xenograft model. Results While B-ALL BM-MSC were less proliferative than those from age-matched healthy donors (HD), the morphology, immunophenotype, differentiation potential and chemoprotection was very similar. Likewise, both BM-MSC populations were equally immunosuppressive in vitro and anti-inflammatory in an in vivo model of severe colitis. Interestingly, BM-MSC failed to impair CD19-CAR T-cell cytotoxicity or cytokine production in vitro using B-ALL cell lines and primary B-ALL cells. Finally, the growth of NALM6 cells was controlled in vivo by CD19-CAR T-cells irrespective of the absence/presence of BM-MSC. Conclusions Collectively, our data demonstrate that pediatric B-ALL and HD BM-MSC equally immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment

  • Urdinguio, Rocío G.|||0000-0003-2736-5758
  • López, Virginia|||0000-0002-0065-7999
  • Fernández Bayón, Gustavo|||0000-0002-0763-0473
  • Díaz de la Guardia, Rafael|||0000-0001-9568-6719
  • Sierra, Marta I.
  • García-Toraño, Estela
  • Pérez, Raúl F.|||0000-0003-4336-9898
  • García, María G.
  • Carella, Antonella
  • Pruneda, Patricia C.
  • Prieto, Cristina|||0000-0002-0812-8100
  • Dmitrijeva, Marija
  • Santamarina-Ojeda, Pablo|||0000-0002-7439-8467
  • Belmonte, Thalia|||0000-0003-1241-6073
  • Mangas, Cristina
  • Diaconu, Elena|||0000-0002-2115-4311
  • Ferrero, Cecilia
  • Tejedor, Juan Ramón|||0000-0002-4061-9698
  • Fernandez-Morera, Juan Luis|||0000-0003-1244-068X
  • Bravo, Cristina
  • Bueno, Clara|||0000-0003-1442-6216
  • Sanjuan-Pla, Alejandra
  • Rodríguez López, Ramón María|||0000-0002-6770-5123
  • Suárez-Álvarez, Beatriz|||0000-0002-3431-4206
  • López-Larrea, Carlos
  • Bernal, Teresa|||0000-0002-2338-513X
  • Colado, Enrique|||0000-0001-8675-8207
  • Balbín, Milagros|||0000-0001-5325-0407
  • García-Suarez, Olivia
  • Chiara, María Dolores|||0000-0002-1112-1583
  • Sáenz De Santa María, Inés|||0000-0002-1868-3001
  • Rodríguez, Francisco|||0000-0001-7909-932X
  • Pando-Sandoval, Ana|||0000-0002-7923-9107
  • Rodrigo-Sáez, Luis|||0000-0003-1717-9345
  • Santos, Laura|||0000-0002-6194-0683
  • Salas, Ana
  • Vallejo-Díaz, Jesús
  • Carrera, Ana C.
  • Rico, Daniel|||0000-0002-6561-2310
  • Hernández-López, Inmaculada
  • Vayá, Amparo
  • Ricart, José María
  • Seto, Edward
  • Sima, Núria|||0000-0003-4097-1402
  • Vaquero, Alejandro|||0000-0002-8735-4156
  • Valledor, Luís|||0000-0002-0636-365X
  • Cañal Villanueva, María Jesús Fátima|||0000-0002-1639-9672
  • Pisano, David|||0000-0002-4895-4124
  • Graña-Castro, Osvaldo
  • Thomas, Tim|||0000-0002-7623-8344
  • Voss, Anne Kathrin|||0000-0002-3853-9381
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Villar-Garea, Ana|||0000-0001-8960-1635
  • Deutzmann, Rainer
  • Fernández, Agustín F.|||0000-0002-3792-4085
  • Fraga, Mario|||0000-0001-8450-2603
Histone H4 acetylation at Lysine 16 (H4K16ac) is a key epigenetic mark involved in gene regulation, DNA repair and chromatin remodeling, and though it is known to be essential for embryonic development, its role during adult life is still poorly understood. Here we show that this lysine is massively hyperacetylated in peripheral neutrophils. Genome-wide mapping of H4K16ac in terminally differentiated blood cells, along with functional experiments, supported a role for this histone post-translational modification in the regulation of cell differentiation and apoptosis in the hematopoietic system. Furthermore, in neutrophils, H4K16ac was enriched at specific DNA repeats. These DNA regions presented an accessible chromatin conformation and were associated with the cleavage sites that generate the 50 kb DNA fragments during the first stages of programmed cell death. Our results thus suggest that H4K16ac plays a dual role in myeloid cells as it not only regulates differentiation and apoptosis, but it also exhibits a non-canonical structural role in poising chromatin for cleavage at an early stage of neutrophil cell death.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Enhanced hemato-endothelial specification during human embryonic differentiation through developmental cooperation between AF4-MLL and MLL-AF4 fusions

  • Bueno, Clara|||0000-0003-1442-6216
  • Calero-Nieto, Fernando|||0000-0003-3358-8253
  • Wang, X.
  • Valdés-Mas, Rafael
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Roca Ho, Heleia|||0000-0001-7324-5234
  • Ayllon, Veronica
  • Real, P. J.
  • Arambilet Mobilla, David|||0000-0001-7372-0082
  • Espinosa, Lluis|||0000-0002-2897-4099
  • Torres, Raul|||0000-0001-9606-0398
  • Agraz-Doblás, Antonio|||0000-0003-1307-4175
  • Varela, Ignacio|||0000-0002-0969-506X
  • De Boer, J.
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Gottgens, B.
  • Marschalek, Rolf|||0000-0003-4870-3445
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
The t(4;11)(q21;q23) translocation is associated with high-risk infant pro-B-cell acute lymphoblastic leukemia and arises prenatally during embryonic/fetal hematopoiesis. The developmental/pathogenic contribution of the t(4;11)-resulting MLL-AF4 (MA4) and AF4-MLL (A4M) fusions remains unclear; MA4 is always expressed in patients with t(4;11)+ B-cell acute lymphoblastic leukemia, but the reciprocal fusion A4M is expressed in only half of the patients. Because prenatal leukemogenesis manifests as impaired early hematopoietic differentiation, we took advantage of well-established human embryonic stem cell-based hematopoietic differentiation models to study whether the A4M fusion cooperates with MA4 during early human hematopoietic development. Co-expression of A4M and MA4 strongly promoted the emergence of hemato-endothelial precursors, both endothelial- and hemogenic-primed. Double fusionexpressing hemato-endothelial precursors specified into significantly higher numbers of both hematopoietic and endothelial-committed cells, irrespective of the differentiation protocol used and without hijacking survival/proliferation. Functional analysis of differentially expressed genes and differentially enriched H3K79me3 genomic regions by RNA-sequencing and H3K79me3 chromatin immunoprecipitation-sequencing, respectively, confirmed a hematopoietic/endothelial cell differentiation signature in double fusion-expressing hemato-endothelial precursors. Importantly, chromatin immunoprecipitation-sequencing analysis revealed a significant enrichment of H3K79 methylated regions specifically associated with HOX-A cluster genes in double fusion-expressing differentiating hematopoietic cells. Overall, these results establish a functional and molecular cooperation between MA4 and A4M fusions during human hematopoietic development.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia

  • López-Millán, Belén|||0000-0002-9757-5454
  • Sánchez Martínez, Diego|||0000-0003-4605-5325
  • Roca Ho, Heleia|||0000-0001-7324-5234
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Molina, Oscar|||0000-0001-7585-4519
  • Díaz de la Guardia, Rafael|||0000-0001-9568-6719
  • Torres, Raul|||0000-0001-9606-0398
  • Fuster, José Luis|||0000-0002-4881-9440
  • Ballerini, Paola
  • Suessbier, U.
  • Nombela-Arrieta, Cesar|||0000-0003-0415-259X
  • Bueno, Clara|||0000-0003-1442-6216
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
B cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer, with cure rates of ∼80%. MLL-rearranged (MLLr) B-ALL (MLLr-B-ALL) has, however, an unfavorable prognosis with common therapy refractoriness and early relapse, and therefore new therapeutic targets are needed for relapsed/refractory MLLr-B-ALL. MLLr leukemias are characterized by the specific expression of chondroitin sulfate proteoglycan-4, also known as neuron-glial antigen-2 (NG2). NG2 was recently shown involved in leukemia invasiveness and central nervous system infiltration in MLLr-B-ALL, and correlated with lower event-free survival (EFS). We here hypothesized that blocking NG2 may synergize with established induction therapy for B-ALL based on vincristine, glucocorticoids, and l-asparaginase (VxL). Using robust patient-derived xenograft (PDX) models, we found that NG2 is crucial for MLLr-B-ALL engraftment upon intravenous (i.v.) transplantation. In vivo blockade of NG2 using either chondroitinase-ABC or an anti-NG2-specific monoclonal antibody (MoAb) resulted in a significant mobilization of MLLr-B-ALL blasts from bone marrow (BM) to peripheral blood (PB) as demonstrated by cytometric and 3D confocal imaging analysis. When combined with either NG2 antagonist, VxL treatment achieved higher rates of complete remission, and consequently higher EFS and delayed time to relapse. Mechanistically, anti-NG2 MoAb induces neither antibody-dependent cell-mediated not complement-dependent cytotoxicity. NG2 blockade rather overrides BM stroma-mediated chemoprotection through PB mobilization of MLLr-B-ALL blasts, thus becoming more accessible to chemotherapy. We provide a proof of concept for NG2 as a therapeutic target for MLLr-B-ALL.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CD133-directed CAR T-cells for MLL leukemia, on-target, off-tumor myeloablative toxicity

  • Bueno, Clara|||0000-0003-1442-6216
  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Zanetti, S. R.|||0000-0002-9052-8751
  • Baroni, Matteo Libero|||0000-0001-8265-2050
  • Sánchez Martínez, Diego|||0000-0003-4605-5325
  • Molina, Oscar|||0000-0001-7585-4519
  • Closa, Adria|||0000-0002-9302-337X
  • Agraz-Doblás, Antonio|||0000-0003-1307-4175
  • Marin, Pedro
  • Eyras, Eduardo|||0000-0003-0793-6218
  • Varela, Ignacio|||0000-0002-0969-506X
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis

  • Agraz-Doblás, Antonio|||0000-0003-1307-4175
  • Bueno, Clara|||0000-0003-1442-6216
  • Rogers, R. B.
  • Roy, A.
  • Schneider, P.
  • Bardini, Michela|||0000-0002-6942-2274
  • Ballerini, Paola
  • Cazzaniga, Giovanni|||0000-0003-2955-4528
  • Moreno, T.
  • Revilla, C.
  • Gut, Marta|||0000-0002-4063-7159
  • Valsecchi, M. G.
  • Roberts, I.
  • Pieters, R.
  • De Lorenzo, P.
  • Varela, Ignacio|||0000-0002-0969-506X
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Stam, R. W.
Bcell acute lymphoblastic leukemia is the commonest childhood cancer. In infants, B-cell acute lymphoblastic leukemia remains fatal, especially in patients with t(4;11), present in ~80% of cases. The pathogenesis of t(4;11)/KMT2A-AFF1 (MLL-AF4) infant B-cell acute lymphoblastic leukemia remains difficult to model, and the pathogenic contribution in cancer of the reciprocal fusions resulting from derivative translocated-chromosomes remains obscure. Here, "multi-layered" genome-wide analyses and validation were performed on a total of 124 de novo cases of infant B-cell acute lymphoblastic leukemia uniformly diagnosed and treated according to the Interfant 99/06 protocol. These patients showed the most silent mutational landscape reported so far for any sequenced pediatric cancer. Recurrent mutations were exclusively found in K-RAS and N-RAS, were subclonal and were frequently lost at relapse, despite a larger number of non-recurrent/non-silent mutations. Unlike non-MLL-rearranged B-cell acute lymphoblastic leukemias, B-cell receptor repertoire analysis revealed minor, non-expanded B-cell clones in t(4;11) infant B-cell acute lymphoblastic leukemia, and RNAsequencing showed transcriptomic similarities between t(4;11) infant B-cell acute lymphoblastic leukemias and the most immature human fetal liver hematopoietic stem and progenitor cells, confirming a "pre-VDJ" fetal cellular origin for both t(4;11) and RAS. The reciprocal fusion AF4-MLL was expressed in only 45% (19/43) of the t(4;11) patients, and HOXA cluster genes are exclusively expressed in AF4-MLL-expressing patients. Importantly, AF4-MLL/HOXA-expressing patients had a significantly better 4-year eventfree survival (62.4% vs. 11.7%, P=0.001), and overall survival (73.7 vs. 25.2%, P=0.016). AF4-MLL expression retained its prognostic significance when analyzed in a Cox model adjusting for risk stratification according to the Interfant-06 protocol based on age at diagnosis, white blood cell count and response to prednisone. This study has clinical implications for disease outcome and diagnostic risk-stratification of t(4;11) infant B-cell acute lymphoblastic leukemia.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Enforced sialyl-Lewis-X (sLeX) display in E-selectin ligands by exofucosylation is dispensable for CD19-CAR T-cell activity and bone marrow homing

  • Sánchez Martínez, Diego|||0000-0003-4605-5325
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Romecín, Paola Alejandra|||0000-0001-6890-5883
  • Vinyoles, Meritxell|||0000-0003-1906-4701
  • Palomo, Marta|||0000-0002-3261-6577
  • Tirado, Néstor
  • Zanetti, S. R.|||0000-0002-9052-8751
  • Juan, Manel|||0000-0002-3064-1648
  • Carlet, Michela
  • Jeremias, Irmela|||0000-0003-1773-7677
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
CD19-directed chimeric antigen receptors (CAR) T cells induce impressive rates of complete response in advanced B-cell malignancies, specially in B-cell acute lymphoblastic leukemia (B-ALL). However, CAR T-cell-treated patients eventually progress due to poor CAR T-cell persistence and/or disease relapse. The bone marrow (BM) is the primary location for acute leukemia. The rapid/efficient colonization of the BM by systemically infused CD19-CAR T cells might enhance CAR T-cell activity and persistence, thus, offering clinical benefits. Circulating cells traffic to BM upon binding of tetrasaccharide sialyl-Lewis X (sLeX)-decorated E-selectin ligands (sialofucosylated) to the E-selectin receptor expressed in the vascular endothelium. sLeX-installation in E-selectin ligands is achieved through an ex vivo fucosylation reaction. Here, we sought to characterize the basal and cell-autonomous display of sLeX in CAR T-cells activated using different cytokines, and to assess whether exofucosylation of E-selectin ligands improves CD19-CAR T-cell activity and BM homing. We report that cell-autonomous sialofucosylation (sLeX display) steadily increases in culture- and in vivo -expanded CAR T cells, and that, the cytokines used during T-cell activation influence both the degree of such endogenous sialofucosylation and the CD19-CAR T-cell efficacy and persistence in vivo. However, glycoengineered enforced sialofucosylation of E-selectin ligands was dispensable for CD19-CAR T-cell activity and BM homing in multiple xenograft models regardless the cytokines employed for T-cell expansion, thus, representing a dispensable strategy for CD19-CAR T-cell therapy. Glyco-engineered enforced sialofucosylation of E-selectin ligands was dispensable for CD19-CAR T-cell activity and BM homing in multiple xenograft models, thus representing an unnecessary strategy for CD19-CAR T-cell therapy
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Near-Haploidy and Low-Hypodiploidy in B-Cell Acute Lymphoblastic Leukemia, When Less Is Too Much

  • Molina, Oscar|||0000-0001-7585-4519
  • Bataller, Alex|||0000-0002-6085-2745
  • Thampi, Namitha|||0000-0001-6166-583X
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • Granada, Isabel|||0000-0002-4275-0104
  • Velasco Puyo, Pablo|||0000-0001-7331-9483
  • Fuster, José Luis|||0000-0002-4881-9440
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
B-cell acute lymphoblastic leukemia (B-ALL) is characterized by an uncontrolled proliferation of blood cells in the bone marrow. A small fraction of B-ALL patients shows abnormally low chromosome numbers, defined as hypodiploidy, in leukemic cells. Hypodiploidy with less than 40 chromosomes is a rare genetic abnormality in B-ALL and is associated to an extremely poor outcome, with low survival rates both in pediatric and adult cases. In this review, we describe the main clinical and genetic features of hypodiploid B-ALL subtypes with less than 40 chromosomes, the current treatment protocols and their clinical outcomes. Additionally, we discuss the potential cellular mechanisms involved on the origin of hypodiploidy, as well as its leukemogenic impact. Studies aiming to decipher the biological mechanisms involved in hypodiploid subtypes of B-ALL with less than 40 chromosomes are crucial to improve the poor survival rates in these patients. Hypodiploidy with less than 40 chromosomes is a rare genetic abnormality in B-cell acute lymphoblastic leukemia (B-ALL). This condition can be classified based on modal chromosome number as low-hypodiploidy (30-39 chromosomes) and near-haploidy (24-29 chromosomes), with unique cytogenetic and mutational landscapes. Hypodiploid B-ALL with <40 chromosomes has an extremely poor outcome, with 5-year overall survival rates below 50% and 20% in childhood and adult B-ALL, respectively. Accordingly, this genetic feature represents an adverse prognostic factor in B-ALL and is associated with early relapse and therapy refractoriness. Notably, half of all patients with hypodiploid B-ALL with <40 chromosomes cases ultimately exhibit chromosome doubling of the hypodiploid clone, resulting in clones with 50-78 chromosomes. Doubled clones are often the major clones at diagnosis, leading to "masked hypodiploidy", which is clinically challenging as patients can be erroneously classified as hyperdiploid B-ALL. Here, we summarize the main cytogenetic and molecular features of hypodiploid B-ALL subtypes, and provide a brief overview of the diagnostic methods, standard-of-care treatments and overall clinical outcome. Finally, we discuss molecular mechanisms that may underlie the origin and leukemogenic impact of hypodiploidy and may open new therapeutic avenues to improve survival rates in these patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers

  • Blanco, Belén
  • Ramírez-Fernández, Ángel
  • Bueno, Clara|||0000-0003-1442-6216
  • Argemí-Muntadas, Lidia
  • Fuentes, Patricia
  • Aguilar-Sopeña, Óscar
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Zanetti, S. R.|||0000-0002-9052-8751
  • Tapia-Galisteo, Antonio
  • Díez-Alonso, Laura
  • Segura-Tudela, Alejandro
  • Castellà, Maria
  • Marzal, Berta
  • Betriu-Méndez, Sergi|||0000-0002-4199-1168
  • Harwood, Seandean L.
  • Compte, Marta
  • Lykkemark, Simon
  • Erce-Llamazares, Ainhoa
  • Rubio-Pérez, Laura
  • Jiménez-Reinoso, Anaïs
  • Domínguez-Alonso, Carmen
  • Neves, Maria
  • Morales, Pablo
  • Paz-Artal, Estela|||0000-0002-0646-2375
  • Guedan, Sonia|||0000-0002-9605-0760
  • Sanz, Laura
  • Toribio, Maria L.
  • Roda-Navarro, Pedro
  • Juan, Manel|||0000-0002-3064-1648
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Álvarez-Vallina, Luis
Chimeric antigen receptor (CAR)-modified T cells have revolutionized the treatment of CD19-positive hematologic malignancies. Although anti-CD19 CAR-engineered autologous T cells can induce remission in patients with B-cell acute lymphoblastic leukemia, a large subset relapse, most of them with CD19-positive disease. Therefore, new therapeutic strategies are clearly needed. Here, we report a comprehensive study comparing engineered T cells either expressing a second-generation anti-CD19 CAR (CART19) or secreting a CD19/CD3-targeting bispecific T-cell engager antibody (STAb-T19). We found that STAb-T19 cells are more effective than CAR-T19 cells at inducing cytotoxicity, avoiding leukemia escape in vitro, and preventing relapse in vivo. We observed that leukemia escape in vitro is associated with rapid and drastic CAR-induced internalization of CD19 that is coupled with lysosome-mediated degradation, leading to the emergence of transiently CD19-negative leukemic cells that evade the immune response of engineered CAR-T19 cells. In contrast, engineered STAb-T19 cells induce the formation of canonical immunologic synapses and prevent the CD19 downmodulation observed in anti- CD19 CAR-mediated interactions. Although both strategies show similar efficacy in short-term mouse models, there is a significant difference in a long-term patient-derived xenograft mouse model, where STAb-T19 cells efficiently eradicated leukemia cells, but leukemia relapsed after CAR-T19 therapy. Our findings suggest that the absence of CD19 downmodulation in the STAb-T19 strategy, coupled with the continued antibody secretion, allows an efficient recruitment of the endogenous T-cell pool, resulting in fast and effective elimination of cancer cells that may prevent CD19-positive relapses frequently associated with CAR-T19 therapies.